WO1994004702A2 - Improved detection and therapy of lesions with biotin/avidin conjugates - Google Patents

Improved detection and therapy of lesions with biotin/avidin conjugates Download PDF

Info

Publication number
WO1994004702A2
WO1994004702A2 PCT/US1993/007754 US9307754W WO9404702A2 WO 1994004702 A2 WO1994004702 A2 WO 1994004702A2 US 9307754 W US9307754 W US 9307754W WO 9404702 A2 WO9404702 A2 WO 9404702A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
protein
detection
targeted
conjugate
Prior art date
Application number
PCT/US1993/007754
Other languages
French (fr)
Other versions
WO1994004702A3 (en
Inventor
David M. Goldenberg
Original Assignee
Immunomedics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics, Inc. filed Critical Immunomedics, Inc.
Priority to EP93920155A priority Critical patent/EP0656115A4/en
Priority to JP6506499A priority patent/JPH09505799A/en
Priority to AU50184/93A priority patent/AU671489B2/en
Priority to CA002142881A priority patent/CA2142881A1/en
Publication of WO1994004702A2 publication Critical patent/WO1994004702A2/en
Publication of WO1994004702A3 publication Critical patent/WO1994004702A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Definitions

  • the present invention relates to improved uses of compositions containing biotin and avidin in methods for detecting and treating pathological conditions with a multi-step process.
  • the targeting antibody is conjugated to an appropriate detecting or therapeutic agent according to processes well known and readily available to one of ordinary skill in the art, as described, for example, in Hansen et al., U.S. Patent No. 3,927,193 and Goldenberg, U.S. Pat. Nos. 4,331,647, 4,348,376, 4,361,544, 4,468,457, 4,444,744, 4,460,459, 4,460,561, 4,624,846 and 4,818,709.
  • Avidin found in egg whites, has a very high binding affinity for biotin, which is a B-complex vitamin (Wilcheck et al.. Anal. Biochem, 171:1, 1988).
  • Streptavidin derived from Streptomyces avidinii , is similar to avidin, but has lower non-specific tissue binding, and therefore often is used in place of avidin. Both avidin and streptavidin have a tetravalency for biotin, thus permitting amplification when the former bind to biotin.
  • a targeting antibody is conjugated with either avidin or biotin and then is injected into a patient, thus localizing the avidin or biotin at a tumor of interest. Thereafter, either biotin or avidin (depending on which was coupled to the targeting antibody) , bearing an imaging isotope, is injected and is localized at the site of the primary antibody by binding to avidin or biotin, respectively.
  • Timing of the second injection after the first one is very critical. Injecting the radiolabeled avidin or biotin too early will increase the avidin/biotin conjugates in the bloodstream and nontargeted tissues, while injecting very late may decrease the amount targeted to the tumor because of reduced retention of the primary antibody at the tumor.
  • Paganelli et al. J. Nucl. Med. 31:735, 1990 and Cancer Res. 51:5960, 1991 disclose a 3-step approach wherein a biotinylated antibody is administered, followed by cold, i.e., non-labeled and non-conjugated, avidin to clear nontargeted antibody, and then a radiolabeled biotin is given which binds to the avidin retained in the body, presumably where the avidin has complexed to the biotinylated antibody.
  • a radiolabeled biotin is given which binds to the avidin retained in the body, presumably where the avidin has complexed to the biotinylated antibody.
  • compositions in methods which will allow for higher and more selective targeting and retaining detection and therapeutic agents to and at pathological lesions and for retaining higher amounts of biotin with the original antibody.
  • the principal object of the present invention is to provide a composition for use in a method of delivering higher amounts and higher target:nontarget ratios of detection or therapeutic agents to targeted lesions.
  • Another objective of the invention is to provide a composition for use in a method of increasing the amount of primary targeting antibody present in a lesion to be detected or treated.
  • Still another object of the invention is to provide a composition for use in a 3- or multiple-step procedure which delivers higher amounts of a detection or therapeutic agent to a lesion.
  • Yet another object of the invention is to provide composition for use in a method of restoring any cleared primary antibody and/or detection or therapeutic agent from a lesion in a later targeting step.
  • a further object of the invention is to provide a composition for use in a method of decreasing the immunogenicity of the targeting agents.
  • Yet another object of the invention is to provide a plurality of uses for these detection or therapeutic agents.
  • the invention provides a composition for use in a method of detecting and/or treating lesions in a patient.
  • the method comprises the steps of (a) parenterally injecting a subject with a targeting composition comprised of (i) a biotin-protein conjugate or (ii) an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced or associated with the targeted lesion, and allowing the protein conjugate to preferentially accrete at the targeted lesion; (b) then, optionally, parenterally injecting a clearing composition comprised of (i) avidin, when the targeting composition is a biotin-protein conjugate, or (ii) biotin, when the targeting composition is an avidin-protein conjugate, and allowing the clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion; (c) parenterally injecting a detection or therapeutic composition comprised of a conjugate of (i) avidin, protein
  • the targeting composition comprised of a biotin-protein conjugate is injected, and no clearing composition is administered; then a detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent is injected and then a detection or therapeutic composition comprised of a conjugate of biotin, protein and detection or therapeutic agent is injected.
  • a targeting composition comprised of a biotin-protein conjugate is first injected, then a clearing composition comprised of avidin is injected, then a detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent is injected, and, lastly, a detection or therapeutic composition comprised of a conjugate of biotin, protein and detection or therapeutic agent is injected.
  • a targeting composition comprised of a biotin-protein conjugate is injected, then a clearing composition comprised of avidin is injected, then a detection or therapeutic composition comprised of a conjugate of biotin, protein and detection or therapeutic agent is injected, and, lastly, another detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent is injected.
  • a targeting composition comprised of a bin in-protein conjugate is injected, then a clearing composition comprised of avidin is injected, then a detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent is injected, and, lastly, a detection or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent is injected.
  • a targeting composition comprised of a biotin-protein conjugate is injected, then a clearing composition comprised of avidin is injected, and, lastly, a detection or therapeutic composition comprised of a conjugate of biotin, protein and detection or therapeutic agent is injected.
  • a targeting composition comprised of a biotin-protein conjugate is injected, then a clearing composition comprised of avidin is injected, then a detection or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent is injected, and, lastly, another detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent is injected.
  • a subject is first injected with a targeting composition comprised of an avidin-protein conjugate, then the subject is injected with a detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent, and, lastly, the subject is injected with a detection or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent.
  • a targeting composition comprised of an avidin-protein conjugate is injected, then a clearing composition comprised of biotin is injected, then a detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent is injected, and, lastly, a detection or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent is injected.
  • an avidin-protein conjugate is injected, then a clearing composition comprised of biotin is injected, then a detection or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent is injected, and, lastly, another detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent is injected.
  • a targeting composition comprised of an avidin-protein conjugate is injected, then a clearing composition comprised of biotin is injected, then a detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent is injected, and, lastly, another detection or therapeutic composition comprised of biotin, protein and detection or therapeutic agent is injected.
  • a targeting composition comprised of an avidin-protein conjugate is injected, then a clearing composition comprised of biotin is injected, and, lastly, a detection or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent is injected.
  • a targeting composition comprised of an avidin-protein conjugate is injected, then a clearing composition comprised of biotin is injected, then a detection or therapeutic composition comprised of a conjugate of biotin, protein and detection or therapeutic agent is injected, and, lastly, another detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent is injected.
  • compositions disclosed herein in 3- and 4-step procedures of the present invention is more advantageous for selective detection and therapy of lesions than the uses disclosed in the prior art.
  • a biotinylated targeting antibody or fragment is injected, followed by the application of avidin as a clearing agent. Then, as a third step, instead of administering biotin-conjugated isotope or drug as taught in the prior art, a lesion- targeting antibody or fragment conjugate is administered.
  • the antibody or fragment is either the same as that of the first step or another such targeting antibody or fragment, and is conjugated with biotin and with a detection or therapeutic agent.
  • Using the lesion- targeting antibody or fragment conjugate forms another lattice of complexation of biotin-avidin-biotin, with the added advantage of targeting to the lesion with the antibody or fragment.
  • the more preferred 4-step embodiments have two basic approaches.
  • the first step is the injection of a biotinylated antibody or fragment and the second step is the injection of an avidin chase.
  • the third step involves the injection of either avidin conjugated with a detection or therapeutic agent, or, alternatively, a biotin conjugated with a detection or therapeutic agent.
  • the fourth step is an injection of a biotinylated anti-lesion antibody or fragment conjugated with a detection or therapeutic agent.
  • the fourth step requires the injection of an anti-lesion antibody or fragment conjugated with avidin and with a detection or therapeutic agent.
  • Each of these 4-step approaches is an improvement, in terms of absolute amount of detection or therapeutic agent delivered and retained at the site of the lesion, as compared to the prior art 2- and 3-step procedures which did not contemplate the use of a biotinylated or avidin-conjugated antibody or fragment bearing additional detection or therapeutic agents for enhancement of the effects as a last step.
  • the sequence can be repeated for additional accumulation of the agents, as needed.
  • the preferred lesion-localizing antibody can be a bispecific or hybrid antibody, whereby at least 2 antibody arms are directed against different epitopes of the same antigen or against different substances associated with the lesion. This is preferred in order to achieve higher levels of accretion and binding in the lesion.
  • compositions of the present invention provide the following improved results over other sequences reported earlier by others: 1. increased binding and retention of primary antibody in the lesion;
  • the detection/therapeutic agents used in the present invention can be any or multiples of the following:
  • A- diagnostic or therapeutic radionuclides e.g. ,alpha-, beta-, gamma-, positron-, x-ray- and fluorescence-emitters; electron- and neutron-capturing agents
  • B- photoactivated dyes for detection or therapy e.g., C- cytotoxic agents (e.g., drugs, toxins, hormones, cytokines, hormone antagonists, receptor antagonists)
  • D- differentiation agents e.g., vitamins, cytokines, autocrines, certain hormones and drugs.
  • the compositions of the present invention can be used to detect (either by internal procedures or by external imaging) and/or treat lesions, including cancers, infectious diseases, cardiovascular diseases and other pathological conditions. Internal detection procedures include intraoperative, intravascular or endoscopic, including laparoscopic, techniques, both surgically invasive and non-mvasive.
  • Avidins are a family of proteins functionally defined by their ability to bind biotin with high affinity and specificity. Avidins are fairly small oligomeric proteins, made up of four identical subunits, each bearing a single binding site for biotin. Avidins can therefore bind up to four moles of biotin per mole of avidin.
  • Avidins include proteins (a) produced by amphibians, reptiles and avians, which are present in their eggs and known as avidin, and (b) produced by a streptomyces,
  • streptomyces avidinii and known as streptavidin.
  • avidin includes all of the above proteins.
  • Proteins are known which preferentially bind marker substances that are produced by or associated with lesions.
  • antibodies can be used against cancer-associated substances, as well as against any pathological lesion that shows an increased or unique antigenic marker, such as against substances associated with cardiovascular lesions, such as, vascular clots including thrombi and emboli, myocardial infarctions and other organ infarcts, atherosclerotic plaques; inflammatory lesions; and infectious and parasitic agents. Examples of appropriate applications are provided in the above-referenced Goldenberg patents and applications.
  • the cancer states include carcinomas, melanomas, sarcomas, neuroblastomas, leukemias, lymphomas, gliomas and myelomas.
  • infectious diseases include those caused by invading microbes or parasites.
  • microbe denotes virus, bacteria, rickettsia, mycoplasma, protozoa, fungi and like microorganism-.
  • parasite denotes infectious, generally microscopic or very small multicellular invertebrates, or ova or juvenile forms thereof, which are susceptible to antibody-induced clearance or lytic or phagocytic destruction, e.g., malarial parasites, spirochetes and the like, including helminths, while "infectious agent” or "pathogen” denotes both microbes and parasites.
  • the protein substances useful in the present invention include protein, peptide, polypeptide, glycoprotein, lipoprotein, or the like, e.g. hormones, lymphokines, growth factors, albumin, cytokines, enzymes, immune modulators, receptor proteins, antibodies and antibody fragments.
  • antibodies and antibody fragments are antibodies and antibody fragments.
  • antibodies and antibody fragments are meant generally immunoglobulins or fragments thereof that specifically bind to antigens to form immune complexes.
  • the antibody may be whole immunoglobulin of any class, e.g., IgG, IgM, IgA, IgD, IgE, chimeric or hybrid antibodies with dual or multiple antigen or epitope specificities. It can be a polyclonal antibody, preferably an affinity-purified antibody from a human or an appropriate animal, e.g., a primate, goat, rabbit, mouse or the like. Monoclonal antibodies are also suitable for use in the present invention, and are preferred because of their high specificities. They are readily prepared by what are now considered conventional procedures of immunization of mammals with immunogenic antigen preparation, fusion of immune lymph or spleen cells with an immortal myeloma cell line, and isolation of specific hybridoma clones.
  • IgG, IgM, IgA, IgD, IgE chimeric or hybrid antibodies with dual or multiple antigen or epitope specificities.
  • It can be a polyclonal antibody, preferably an affinity-purified antibody from
  • monoclonal antibodies More unconventional methods of preparing monoclonal antibodies are not excluded, such as interspecies fusions and genetic engineering manipulations of hypervariable regions, since it is primarily the antigen specificity of the antibodies that affects their utility in the present invention. It will be appreciated that newer techniques for production of monoclonals can also be used, e.g., human monoclonals, interspecies monoclonals, chimeric (e.g. , human/mouse) monoclonals, genetically engineered antibodies and the like.
  • Antibody fragments useful in the present invention include F(ab') 2 , F(ab) 2 , Fab', Fab, Fv and the like including hybrid fragments. Preferred fragments are Fab', F(ab') 2 , Fab, and F(ab) 2 . Also useful are any subfragments retainingthehypervariable, antigen-binding region of an immunoglobulin and having a size similar to or smaller than a Fab' fragment. This will include genetically engineered and/or recombinant proteins, whether single-chain or multiple-chain, which incorporate an antigen-binding site and otherwise function in vivo as targeting vehicles in substantially the same way as natural immunoglobulin fragments.
  • Fab' antibody fragments may be conveniently made by reductive cleavage of F(ab') 2 fragments, which themselves may be made by pepsin digestion of intact immunoglobulin.
  • Fab antibody fragments may be made by papain digestion of intact immunoglobulin, under reducing conditions, or by cleavage of F(ab) 2 fragments which result from careful papain digestion of whole immunoglobulin. The fragments may also be produced by genetic engineering.
  • Multispecific, including bispecific and hybrid, antibodies and antibody fragments are especially preferred in the present invention for detecting and treating lesions and are comprised of at least two different substantially monospecific antibodies or antibody fragments, wherein at least two of said antibodies or antibody fragments specifically bind to at least two different antigens produced or associated with the targeted lesion or at least two different epitopes or molecules of a marker substance produced or associated with the targeted lesion.
  • Multispecific antibodies and antibody fragments with dual specificities can be prepared analogously to the anti-tumor marker hybrids disclosed in U.S. Pat. No. 4,361,544.
  • Other techniques for preparing hybrid antibodies are disclosed in, e.g.. U.S. Pat. No. 4,474,893 and 4,479,895, and in Milstein et al., Immunol. Today, 5,299(1984).
  • proteins having a specific immunoreactivity to a marker substance of at least 60% and a cross-reactivity to other antigens or non-targeted substances of less than 35%.
  • antibodies against tumor antigens and against pathogens are known.
  • antibodies and antibody fragments which specifically bind markers produced by or associated with tumors or infectious lesions, including viral, bacterial, fungal and parasitic infections, and antigens and products associated with such microorganisms have been disclosed, inter alia, in Hansen et al., U.S. Patent 3,927,193 and Goldenberg U.S. Patents 4,331,647, 4,348,376, 4,361,544, 4,468,457, 4,444,744, 4,818,709 and 4,624,846.
  • antibodies against an antigen e.g., a gastrointestinal, lung, breast, prostate, ovarian, testicular, brain or lymphatic tumor, a sarcoma or a melanoma, are advantageously used.
  • MAbs monoclonal antibodies against infectious disease agents
  • Antimvcoplasmal MAbs Mycoplasma arthritidis M. hyorhinis M. orale
  • MAbs against the gpl20 glycoprotein antigen of human immunodeficiency virus 1 are known, and certain of such antibodies can have an immunoprotective role in humans. See, e.g., Rossi et al., Proc. Natl. Acad. Sci. USA, 86:8055-8058, 1990. Other MAbs against viral antigens and viral induced antigens are also known. This shows that proper selection of the epitope can distinguish between a therapeutic and non-therapeutic target.
  • MAbs against malaria parasites can be directed against the sporozoite, merozoite, schizont and gametocyte stages.
  • Monoclonal antibodies have been generatedagainst sporozoites (circumsporozoite antigen) , and have been shown to neutralize sporozoites in vitro and in rodents (N. Yoshida et al.. Science 207:71-73, 1980) .
  • MAbs have been developed against schistosomular surface antigens and have been found to act against schistosomulae in vivo or in vitro (Simpson et al., Parasitology, 83:163-177, 1981; Smith et al., Parasitology, 84:83-91, 1982; Gryzch et al. , J. Immunol., 129:2739-2743, 1982; Zodda et al. , J. Immunol. 129:2326- 2328, 1982; Dissous et al. , J. Immunol., 129:2232-2234, 1982) .
  • Trypanosoma cruzi is the causative agent of Chagas' disease, and is transmitted by blood-sucking reduviid insects.
  • a MAb has been generated that specifically inhibits the differentiation of one form of the parasite to another (epimastigote to trypomastigote stage) in vitro, and which reacts with a cell-surface glycoprotein; however, this antigen is absent from the mammalian (bloodstream) forms of the parasite (Sher et al.. Nature, 300:639-640, 1982).
  • Suitable MAbs have been developed against most of the microorganisms (bacteria, viruses, protozoa, other parasites) responsible for the majority of infections in humans, and many have been used previously for in vitro diagnostic purposes. These antibodies, and newer MAbs that can be generated by conventional methods, are appropriate for use in the present invention.
  • Proteins useful for detecting and treating cardiovascular lesions include fibrin-specific proteins, for example, fibrinogen, soluble fibrin, antifibrin antibodies and fragments, fragment E_ (a 60 kDa fragment of human fibrin made by controlled plasmin digestion of crosslinked fibrin) , plasmin (an enzyme in the blood responsible for the dissolution of fresh thrombi) , plasminogen activators (e.g., urokinase, streptokinase and tissue plasminogen activator) , heparin, and fibronectin (an adhesive plasma glycoprotein of 450 kDa) and platelet-directed proteins, for example, platelets, antiplatelet antibodies and antibody fragments, anti- activated platelet antibodies, and anti-activated- platelet factors, which have been reviewed by Koblik et al., Semin. Nucl . Med. , 19:221-237 (1989).
  • fibrinogen activators e.g., urokinase, streptokina
  • gamma-emitters, positron-emitters, x-ray emitters and fluorescence-emitters are suitable for localization and/or therapy, while beta- and alpha- emitters and electron- and neutron-capturing agents also can be used for therapy.
  • Suitable radioisotopes for use in the present invention include: Astatine-211, Iodine-123, Iodine-125, Iodine-126, Iodine-131, Iodine-133, Bismuth-212, Bromine- 77, Indium-Ill, Indium-113m, Gallium-67, Gallium-68, Ruthenium-95, Ruthenium-97, Ruthenium-103, Ruthenium-105, Mercury-107, Mercury-203, Rhenium-186, Rhenium-188, Tellurium-121m, Tellurium-122m, Tellurium-125m, Thulium- 165, Thulium-167, Thulium-168, Technetium-99m, Fluorine- 18, Silver-Ill, Platinum-197, Palladium-109, Copper-67, Phosphorus-32, Phosphorus-33, Yttri --.-90, Scandium-47, Samarium-153, Lutetium-177, Rhodium-105, Pra
  • Isotopes preferred for external imaging include:Iodine-123, Iodine-131, Indium-Ill, Gallium-67, Ruthenium-97, Technetium-99m, Cobalt-57, Cobalt-58,
  • Isotopes most preferred for internal detection include: Iodine-125, Iodine-123, Iodine-131, Indium-Ill, Technetium-99m and Gallium-67.
  • Isotopes preferred for therapeutic use include: Iodine-125, Iodine-131, Rhenium-186, Rhenium-188, Silver- Ill, Platinum-197, Palladium-109, Copper-67, Phosphorus- 32, Phosphorus-33, Yttrium-90, Scandium-47, Samarium-153,
  • drugs and toxins which have cytotoxic effects on cells. They are to be found in compendia of drugs and toxins, such as the Merck Index, Goodman and Gilman, and the like, and in the references cited above. Any such drug can be conjugated to or loaded onto the antibody by conventional means well know in the art, and illustrated by analogy to those described above.
  • the present invention also contemplates dyes used, for example, in photodynamic therapy, conjugated to proteins, biotin or avidin and used in conjunction with appropriate nonionizing radiation.
  • cytotoxic agents useful in the present invention are listed in Goodman et al., "The Pharmacological Basis of Therapeutics," Sixth Edition, A.G. Gilman et al, eds./ Macmillan Publishing Co. New York, 1980.
  • taxol nitrogen mustards, such as mechlorethamine, cyclophosphamide, melphalan, uracil mustard and chlorambucil; ethylenimine derivatives, such as thiotepa; alkyl sulfonates, such as busulfan; nitrosoureas, such as carmustine, lomustine, semustine and streptozocin; triazenes, such as dacarbazine; folic acid analogs, such as methotrexate; pyri idine analogs, such as fluorouracil, cytarabine and azaribine; purine analogs, such as mercaptopurine and thioguanine; vinca alkaloids, such as vinblastine and vincristine; antibiotics, such as dactinomycin, daunorubicin, doxorubicin, bleomycin, mithramycin and mitomycin; enzymes, such as L-aspara
  • Drugs that interfere with intracellular protein synthesis can also be used in the methods of the present invention; such drugs are known to these skilled in the art and include puromycin, cycloheximide, and ribonuclease.
  • Toxins can also be used in the methods of the present invention.
  • Toxins useful as therapeutics are known to those skilled in the art and include plant and bacterial toxins, such as, abrin, alpha toxin, diphtheria toxin, exotoxin, gelonin, pokeweed antiviral protein, ricin, and saporin.
  • Toxins in their native form require a minimum of three different biochemical functions to kill cells: a cell binding function, a cytotoxic function, and a function to translocate the toxic activity into the cells.
  • modified toxins useful in the present invention differ from native toxins in that the domain providing the cell binding function of the native toxin is nonfunctioning because the domain is missing partially or totally.
  • Other therapeutic agents useful in the present invention include anti-DNA, anti-RNA, anti-protein and anti-chromatin cytotoxic or antimicrobial agents.
  • the proteins useful in the present invention may be labeled or conjugated by a variety of methods known in the art. Many of these methods are disclosed in the above-referenced U.S. Patents and Patent Applications. See also, Rayudu, OP. cit. : and Childs et al., J. Nuc. Med.. 26. 293(1985). Any conventional method of radiolabeling which is suitable for labeling isotopes for in vivo use will be generally suitable for labeling detection agents according to the present invention.
  • the avidin/streptavidin, biotin or proteins may be conjugated to therapeutic agents such as drugs, toxins, boron addends, isotopes, fluorescent dyes activated by nonionizing radiation, hormones, autocrines, cytokines, cytoprotective agents, etc., by methods known to those skilled in the art.
  • therapeutic agents such as drugs, toxins, boron addends, isotopes, fluorescent dyes activated by nonionizing radiation, hormones, autocrines, cytokines, cytoprotective agents, etc.
  • Biotin can be readily conjugated to proteins (including antibodies and their fragments) via the proteins* lysine and cysteine residues, and, if available, their oxidized carbohydrate groups.
  • the detection or therapeutic agents may be treated by methods, known to those skilled in the art, to permit the agents to be more easily conjugated to biotin, avidin/streptavidin or targeting protein as required.
  • Loading of drugs onto a carrier will depend upon the potency of the drug, the efficiency of the antibody targeting and the efficacy of the conjugate once it reaches its target. In most cases, it is desirable to load at least 20, preferably 50 and often 100 or more molecules of a drug on a carrier.
  • the ability to partially or completely detoxify a drug as a conjugate, while it is circulation, can reduce systemic side effects of the drug and permit its use when systemic administration of the unconjugated drug would be unacceptable.
  • Toxins will often be less heavily loaded than drugs, but it will still be advantageous to load at least 1, preferably 5, and in some cases 10 or more molecules of toxin on a carrier and load at least one carrier chain on the antibody for targeted delivery.
  • the amount of drug or toxin is generally about 0.25 to 5 times, preferably 1-3 times, the amount of antibody or antibody fragment, and the time of reaction is about 10 to 120 minutes, preferably 30-90 minutes .
  • a physiological solution of the protein conjugate is advantageously metered into sterile vials, e.g., at a unit dosage of about 1.0 - 500 mg protein conjugate/vial, and the vials are either stoppered, sealed and stored at low temperature, or lyophilized, stoppered, sealed and stored. Variations and modifications of these formulations will be readily apparent to the ordinary skilled artisan, as a function of the individual needs of the patient or treatment regimen, as well as of variations in the form in which the radioisotopes may be provided or may become available.
  • the present invention includes uses of the compositions wherein there is a reduction of the immunogenicity of (a) avidin (b) the therapeutic agent moiety of a conjugate, e.g., the toxin, or (c) the targeting composition, by coupling the immunogenic agent with a carbohydrate polymer or polyol groups.
  • a conjugate e.g., the toxin
  • c) the targeting composition by coupling the immunogenic agent with a carbohydrate polymer or polyol groups.
  • useful carbohydrates or polyol groups include dextran, polysaccharides, polyethylene glycol (PEG) , and the like.
  • the biotinylated or avidin (streptavidin) lesion-targeting protein can be injected parentally, usually at a protein dose of 0.5 to 50 mg, more preferably within a dose range of 1.0 to 20.0 mg, and still more preferably at 2.0 to 10.0 mg. This can be administered as a single injection or in divided doses.
  • a dose of unlabeled clearing agent such as 2.0 to 200.0 mg avidin (more preferably about a ratio of 2.5:1 to 10:1 of avidin to biotinylated protein) when a biotinylated lesion-targeting protein is used as the first agent, is administered parenterally.
  • the clearing agent can be given as a single injection or in divided doses, wherein administering the clearing agent in 2 doses is preferred in certain circumstances.
  • the third step involves injection of the biotinylated (or avidin-conjugated) lesion-targeting protein, as in the first step, but conjugated to a detection or therapeutic agent.
  • the lesion-targeting protein can be identical to that of the first step, or another protein capable of similarly targeting the lesion, such as a second targeting antibody.
  • the third step's reagents can be administered parenterally within 24 hrs of the 2nd step, but also at up to 3 days later.
  • the third step involves 111-In conjugated to biotin attached to a lesion-targeting antibody or antibody fragment.
  • planar and single-photon emission computed tomography scans are made with a gamma camera equipped with the appropriate collimator and selecting the appropriate energy windows for the detection isotope being used, such as 173 keV and 247 keV for 111-In.
  • the biotinylated or avidin (streptavidin) lesion-targeting protein can be injected parenterally, usually at a protein dose of 2 to 200 mg, more preferably within a dose range of 5 to 50 mg, more preferably at 2.0 to 10.0 mg. This can be administered as a single or as divided injections.
  • a dose of unlabeled clearing agent such as 2.5- to 10-times the dose of the first step's protein (which can be determined also by measuring the amount of first agent's protein circulating in the blood at the time of the second step's injection) , is given parenterally.
  • the clearing agent can be given as a single injection or in divided doses, dividing the administration of the clearing agent into at least 2 doses may be preferable, usually within a short period, such as within 2 hrs.
  • a dose of 2 to 200 mg protein, more preferably 5 to 50 mg, of biotin conjugated with a detection or therapeutic agent, as appropriate is administered parenterally either as a single dose or in divided doses.
  • a fourth step involves the parenteral administration of avidin (or streptavidin) conjugated to a lesion-targeting agent, which can be the same or different from the first lesion-targeting agent, to which a detection or therapeutic agent, as appropriate, is also attached.
  • the third step can involve the biotinylated lesion-targeting protein conjugated with a detection or therapeutic agent, as appropriate, and the fourth step the detection or therapeutic agent, as appropriate, conjugated to avidin (or streptavidin) .
  • the third step's reagents can be administered within 24 hrs of the 2nd step, but also at up to 7 days or more later, depending upon the targeting time and clearance involving the first two steps.
  • the fourth step can be initiated within 24 hrs of the third step, but also up to 7 days or more later.
  • Routes of administration include intravenous, intraarterial, intrapleural, intraperitoneal, intrathecal, subcutaneous or by perfusion.
  • an application of the lesion-specific or lesion- associated protein disclosed hereinabove is for magnetic resonance imaging (mri) .
  • a suitably radiolabeled antibody/fragment or an antibody/fragment bearing a mr image enhancing agent is administered with the intention of obtaining an image of the lesion.
  • the uses of compositions in methods according to the invention can be practiced either with scintigraphic or magnetic resonance imaging agents. A combination of these imaging agents can also be used, although this requires more complex instrumentation and data processing.
  • Scintigraphic imaging according to the method of the invention is effected by obtaining a scintigram of the lesion of interest.
  • the scintigram is normally taken by a gamma imaging camera having one or more windows for detection of energies in the 50-500 keV range.
  • Use of radioisotopes with higher energy, beta, or positron emissions would entail use of imaging cameras with the appropriate detectors, all of which are conventional in the art.
  • the scintigraphic data can be stored in a computer for later processing.
  • compositions according to the present invention can enhance the methods disclosed in these references.
  • Magnetic resonance imaging (mri) is effected in an analogous manner to scintigraphic imaging except that the imaging agents will contain magnetic resonance (mr) enhancing species rather than radioisotopes. It will be appreciated that the magnetic resonance phenomenon operates on a different principle from scintigraphy.
  • the signal generated is correlated with the relaxation times of the magnetic moments of protons in the nuclei of the hydrogen atoms of water molecules in the region to be imaged.
  • the magnetic resonance image enhancing agent acts by increasing the rate of relaxation, thereby increasing the contrast between water molecules in the region where the imaging agent accretes and water molecules elsewhere in the body.
  • the effect of the agent is to decrease both Tj and T 2 , the former resulting in greater contrast while the latter results in lesser contrast. Accordingly, the phenomenon is concentration-dependent, and there is normally an optimum concentration of a paramagnetic species for maximum efficacy.
  • This optimal concentration will vary with the particular agent used, the locus of imaging, the mode of imaging, i.e., spin-echo, saturation-recovery, inversion-recovery and/or various other strongly 1_- dependent or T 2 -dependent imaging techniques, and the composition of the medium in which the agent is dissolved or suspended. These factors, and their relative importance are known in the art. See, e.g., Pykett, Scientific American. 246. 78(1982); Runge et al.. Am. J. Radiol.. 141. 1209(1983).
  • the mr image enhancing agent must be present in sufficient amounts to enable detection by an external camera, using magnetic field strengths which are reasonably attainable and compatible with patient safety and instrumental design.
  • the requirements for such agents are well known in the art for those agents which have their effect upon water molecules in the medium, and are disclosed, inter alia, in Pykett, op. cit. , and Runge et al. , op., cit.
  • Preparation of protein, biotin or avidin/streptavidin (molecule) conjugated to a magnetic resonance image enhancing agent can be effected by a variety of methods.
  • a reagent having a long tail to which are attached a multiplicity of chelating groups for binding the ions.
  • a tail can be a polymer such as a polylysine, polysaccharide, or other derivatized or derivatizable chain having pendant groups to which can be bound chelating groups such as, e.g., ethylenediaminetetra- acetic acid (EDTA) , diethylenetriaminepentaacetic acid (DTPA) , porphyrins, polya ines, crown ethers, bis-thio- semicarbazones, polyoximes, and like groups known to be useful for this purpose.
  • EDTA ethylenediaminetetra- acetic acid
  • DTPA diethylenetriaminepentaacetic acid
  • porphyrins polya ines, crown ethers, bis-thio- semicarbazones, polyoximes, and like groups known to be useful for this purpose.
  • the chelate is normally linked to the molecule by a group which enables formation of a bond to the molecule with minimal loss of immunoreactivity and minimal aggregation and/or internal cross-linking.
  • Other, more unusual, methods and reagents for conjugating chelates to antibodies are disclosed in U.S. Patent 4,824,659 to Hawthorne, entitled “Antibody Conjugates", issued April 25, 1989.
  • MRI contrast agents are well known in the art and include, for example. Gadolinium, Iron, Manganese, Rhenium, Europium, Lanthanium, Holmium, and Ferbium.
  • the mr scans are stored in a computer and the images processed analogously to the scintigraphic data.
  • these embodiments constitute improved compositions and uses thereof for amplification of protein, especially antibody and antibody fragments, targeting for detecting and therapy of cancer and other pathological condition-- *
  • Example 1 Conjugating Antibody or Antibody Fragment to Biotin via Lvsine.
  • a non-amine containing buffer e.g. ,borate, phosphate, etc.
  • a co-solvent such as dimethylformamide (DMF) or dimethylsulfoxide (DMSO)
  • DMF dimethylformamide
  • DMSO dimethylsulfoxide
  • the reaction solution is stirred for 1-24 hours and kept at a temperature of 4°C to 37 ⁇ C.
  • the modified protein is separated from unbound biotin and other low molecular weight contaminants by size-exclusion chromatography and/or dialysis.
  • Example 2 Conjugating Antibody or Antibody Fragment to Biotin via Cvsteine.
  • the reaction solution is let stand 5-120 min. at a temperature of 4°-37°C.
  • the reduced protein is separated from unreacted thiol by size-exclusion chromatography in 50 mM acetate buffer, pH 4.5. Protein concentration and the number of thiol groups per antibody molecule may be determined at this time.
  • the reduced antibody at a concentration of 1-20 mg/ml in a non-amine containing buffer (e.g., phosphate) at a neutral pH (5.0-7.0) is mixed with a 1-100 molar excess of biotin-maleimide (N-biotinyl-N-[6-maleimido hexanoyl]hydrazide) (Sigma Chem. Co) .
  • a co-solvent e.g., DMF or DMSO, may be added to provide a final concentration of up to 20% to facilitate reactant solubility.
  • the reaction solution is stirred for 1-24 hours at a temperature between 4-37 ⁇ C.
  • the biotinylated protein is separated from unbound biotin and other low molecular weight contaminants by size-exclusion chromatography and/or dialysis.
  • Example 3 Conjugating Antibody or Antibody Fragments to Biotin via a Carbohydrate.
  • Antibody at a concentration of 1-20 mg/ml is treated with sodium metaperiodate to a final concentration of 0.1-10 mg/ml in phosphate buffered saline at room temperature for 1-4 hours. Ethylene glycol is added to decompose the remaining periodate.
  • the oxidized IgG is purified from low molecular weight contaminants by size- exclusion chromatography in phosphate buffer.
  • the oxidized antibody (1-20 mg/ml) is reacted with a 1-100 molar excess of biotin-hydrazide (Pierce Chemical Co.) in a non-amine buffer (e.g., phosphate, carbonate, etc.) at neutral pH (5.0-8.0) for 1-48 hours at 4-37°C. After the optimum time for coupling, the formed hydrazones are reduced by the addition of sodium cyanoborohydride with pH adjustment to >7.
  • the biotinylated antibody is purified by size-exclusion chromatography and/or dialysis.
  • Example 4 Conjugating Antibody or Antibody Fragments to Biotin via addended Thiol Groups
  • An antibody or antibody fragment at a concentration of 1-20 mg/ml in a non-amine containing buffer (e.g., borate, carbonate, etc.) at a suitable concentration (0.05-0.5M) and pH (7-10) is mixed with a 1-100 molar excess of 2-iminothiolane hydrochloride (Pierce Chemical Co.).
  • the reaction mixture is made 1-100 mM in EDTA to help prevent disulfide bond formation and held at 4-37° for from 1-4 hours.
  • the modified protein is purified by size-exclusion chromatography in a neutral to slightly acidic buffer (e.g., acetate, citrate, etc.) pH 5.0-7.0.
  • the purified sulfhydryl substituted antibody (1-20 mg/ml) is mixed with a 1-100 molar excess of biotin maleimide.
  • a co-solvent e.g. , DMF or DMSO, may be added to a final concentration of up to 20% to facilitate reactant solubility.
  • the reaction solution is stirred for 1-24 hours at a temperature between 4-37 ⁇ C.
  • the biotinylated protein is separated from unbound biotin and other low molecular weight contaminants by size-exclusion chromatography and/or dialysis.
  • an antibody F(ab') 2 fragment obtained by pepsin digestion of the intact antibody
  • phosphate buffer at pH 6-8 is treated with a freshly prepared solution of L-cysteine to give a final cysteine concentration of 1-50 mg/ml.
  • the reaction is allowed to proceed for 1-4 hours at 25-37 ⁇ C.
  • the Fab' fragment is purified from low molecular weight contaminants by size-exclusion chromatography in an acidic buffer (e.g., acetate, etc.) at pH 4.0-6.0.
  • the Fab' fragment is reacted with a 1-100 molar excess of biotin-maleimide at pH 5.0-7.0.
  • a co- solvent e.g., DMF or DMSO
  • DMF or DMSO may be added to a final concentration of up to 20% to facilitate reactant solubility.
  • the reaction is stirred for 1-24 hours at a temperature between 4-37 ⁇ C.
  • the biotinylated antibody fragment is separated from unbound biotin and other low molecular weight contaminants by size-exclusion chromatography and/or dialysis.
  • biotinylated antibody A small amount of biotinylated antibody is heated to 56° in 0.1M phosphate buffer for 10 minutes and enzymatically digested with small volumes of 1% pronase (Sigma Chemical Co.). The digestion is allowed to proceed overnight.
  • the digest is analyzed with a 10 uM solution of avidin saturated with a 100 uM solution of 2- (4'-hydroxyazobenzene)-benzoic acid (HABA) in 0.1M phosphate buffer, pH 7.0.
  • the avidin-HABA solution is titrated with increasing volumes of digested biotinylated antibody as well as a standard biotin solution containing 1-10 mM of biotin. The change in absorbance at 500 nM for each is determined, and the concentration of biotin in the pronase digested biotinylated antibody calculated from reference to the standard curve of the titration of biotin with avidin-HABA.
  • a patient diagnosed by sigmoidoscopy to have a colonic neoplasm is injected i.v. with 1.0 mg. of a biotinylated MN-14 monoclonal antibody IgG against carcinoembryonic antigen (CEA) .
  • CCA carcinoembryonic antigen
  • Two days later 5 mg of unlabeled avidin (in two divided doses, 20 min apart) is injected i.v.
  • 1 mg of biotinylated Mu-9 antibody IgG against colon-specific antigen-p (CSAp) labeled with 111-In (4 mCi) is injected i.v.
  • the patient is scanned with a gamma camera 2 hrs later, and a focus of increased radioactivity is detected in the region of the sigmoid colon, in agreement with the sigmoidoscopy findings.
  • a patient with suspected atherosclerotic plaques in various arteries is injected i.v. with 2.0 mg of the biotinylated LL1 monoclonal antibody F(ab') 2 against macrophage.
  • One day later 6 mg of unlabeled avidin (in two divided doses, 15 min apart) is injected i.v.
  • 1 mg of biotinylated LL1 IgG conjugated with 5 mCi of 111-In is injected i.v., and the patient scanned with a gamma camera 3 hours later.
  • Foci of abnormal radioactivity is found in a tibial artery, the abdominal aorta, and possibly in a right cerebral vessel.
  • a patient with several small colonic carcinoma metastases to the liver is injected i.v. with a dose of 10 mg of a first composition comprised of biotinylated MN-14 anti-CEA IgG monoclonal antibody.
  • a clearing composition of 25 mg avidin is injected i.v. (in two divided doses, 30 min apart) .
  • a dose of 10 mg of a second composition of biotin having 25 mCi 90-Y is injected i.v.
  • a second therapy dose of a third composition of 20 mCi 90-Y conjugated to avidin-labeled MN-14 anti-CEA IgG (10 mg) is given i.v. Based upon liver CT scans and plasma CEA titers performed 8 weeks later, significant regression of the liver tumor lesions is observed.
  • a patient with a right lung adenocarcinoma is injected with biotinylated "RS7" anti-lung-cancer IgG i.v. Four days later, avidin is injected i.v. (in two divided doses, 60 minutes apart) . After another 2 days, a dose of biotinylated RS7 conjugated with aminodextran- doxorubicin, according to the methods described in the Shih patent (USP 4,699,784), is administered i.v. Five days later, a dose of streptavidin conjugated with aminodextran-doxorubicin is administered i.v. Four weeks later, chest CT indicates that the right lung lesion is decreased in size by about 50 percent.

Abstract

Uses of compositions in methods for detecting and/or treating targeted lesions in a patient are provided. The compositions used are comprised of a targeting composition comprising a biotin and targeting protein conjugate or an avidin and targeting protein conjugate; optionally, a clearing composition comprised of avidin, when the targeting composition is a biotin conjugate, or biotin, when the targeting composition is an avidin conjugate; a detection or therapeutic composition comprised of a conjugate of avidin or biotin with a targeting protein and detection or therapeutic agent; and, optionally, another detection or therapeutic composition comprised of avidin or biotin conjugated to a detection or therapeutic agent. The compositions, methods of use, and kits for use are also provided.

Description

IMPROVED DETECTION AND THERAPY OF LESIONS WITH BIOTIN/AVIDIN CONJUGATES
BACKGROUND OF THE INVENTION
1- Field of the Invention
The present invention relates to improved uses of compositions containing biotin and avidin in methods for detecting and treating pathological conditions with a multi-step process.
2- Description of the Prior Art
Antibodies against different determinants associated with pathological and normal cells, as well as associated with pathogenic microorganisms, have been used for the detection and treatment of a wide variety of pathological conditions, or lesions. The targeting antibody is conjugated to an appropriate detecting or therapeutic agent according to processes well known and readily available to one of ordinary skill in the art, as described, for example, in Hansen et al., U.S. Patent No. 3,927,193 and Goldenberg, U.S. Pat. Nos. 4,331,647, 4,348,376, 4,361,544, 4,468,457, 4,444,744, 4,460,459, 4,460,561, 4,624,846 and 4,818,709.
When detecting a lesion, a high signal-to-background ratio needs to be achieved. Therapy also requires a high absolute accretion of the therapeutic agent in the lesion, as well as a reasonably long duration of uptake and binding. High background levels of non-targeting antibody have long been recognized as a major impediment to high target: background ratios being achieved. To overcome this impediment, various methods have been developed, such as those described in the above- referenced Goldenberg patents.
Still other methods have been developed to increase the target:background ratios of the detection or therapeutic agents, such as pre-targeting and biotin/avidin approaches, as described, for example, in Goodwin et al., U.S. Patent No. 4,863,713; Goodwin et al., J. Nucl. Hed. 29:226, 1988; Hnatowich et al., J. Nucl. Med. 28:1294, 1987; Oehr et al., J. Nucl. Med. 29:728, 1988; Klibanov et al.> J. Nucl. Med. 29:1951, 1988; Sinitsyn et al. , J. Nucl. Med. 30:66, 1989; Kalofonos et al., J. Nucl. Med. 31:1791, 1990; Schechter et al.. Int. J. Cancer 48:167, 1991; Paganelli et al.. Cancer Res. 51:5960, 1991; Paganelli et al., Nucl. Med. Commun. 12:211, 1991; Stickney et al.. Cancer Res. 51:6650, 1991; and Yuan et al.. Cancer Res. 51:3119, 1991.
Avidin, found in egg whites, has a very high binding affinity for biotin, which is a B-complex vitamin (Wilcheck et al.. Anal. Biochem, 171:1, 1988). Streptavidin, derived from Streptomyces avidinii , is similar to avidin, but has lower non-specific tissue binding, and therefore often is used in place of avidin. Both avidin and streptavidin have a tetravalency for biotin, thus permitting amplification when the former bind to biotin.
In a prior art 2-step procedure, a targeting antibody is conjugated with either avidin or biotin and then is injected into a patient, thus localizing the avidin or biotin at a tumor of interest. Thereafter, either biotin or avidin (depending on which was coupled to the targeting antibody) , bearing an imaging isotope, is injected and is localized at the site of the primary antibody by binding to avidin or biotin, respectively.
Timing of the second injection after the first one is very critical. Injecting the radiolabeled avidin or biotin too early will increase the avidin/biotin conjugates in the bloodstream and nontargeted tissues, while injecting very late may decrease the amount targeted to the tumor because of reduced retention of the primary antibody at the tumor.
Paganelli et al. (Int. J. Cancer 2:121, 1988) and Kalofonos et al. (J. Nucl. Med. 31:1791, 1990) demonstrated the feasibility of the above approach (the former used biotinylated antibody; the latter used streptavidin-conjugated antibody fortumor localization) . In work reported by Kalofonos et al. (ibid.), 3 of 10 patients showed improved imaging. However, the patients also showed that labeled biotin alone (without antibody pretargeting) could detect tumors in 8 of 10 patients.
Paganelli et al. (J. Nucl. Med. 31:735, 1990 and Cancer Res. 51:5960, 1991) disclose a 3-step approach wherein a biotinylated antibody is administered, followed by cold, i.e., non-labeled and non-conjugated, avidin to clear nontargeted antibody, and then a radiolabeled biotin is given which binds to the avidin retained in the body, presumably where the avidin has complexed to the biotinylated antibody. By this method, Paganelli et al. were able to show, with the exception of the kidneys, high tumor:normal organ ratios. By further examining this 3-step procedure, however, the present inventor has found that cold avidin can reduce the amount of biotin (in the biotinylated antibody) contained in tumor. Further, many of the above-cited studies have demonstrated that avidin is immunogenic, resulting in anti-avidin antibodies which preclude repeated administrations of this agent (and thereby repeated detecting or therapy courses) . Many of these 2- and 3- step approaches using biotin or avidin immunoconjugates have shown improved target:background ratios; however, the administration of a clearing agent, such as avidin, after a biotinylated targeting antibody is first given, not only reduces circulating biotinylated antibody, but also reduces the amount of biotinylated antibody in the target lesion.
Therefore, a need exists for better uses of compositions in methods which will allow for higher and more selective targeting and retaining detection and therapeutic agents to and at pathological lesions and for retaining higher amounts of biotin with the original antibody.
OBJECTS OF THE INVENTION
The principal object of the present invention is to provide a composition for use in a method of delivering higher amounts and higher target:nontarget ratios of detection or therapeutic agents to targeted lesions. Another objective of the invention is to provide a composition for use in a method of increasing the amount of primary targeting antibody present in a lesion to be detected or treated.
Still another object of the invention is to provide a composition for use in a 3- or multiple-step procedure which delivers higher amounts of a detection or therapeutic agent to a lesion.
Yet another object of the invention is to provide composition for use in a method of restoring any cleared primary antibody and/or detection or therapeutic agent from a lesion in a later targeting step.
A further object of the invention is to provide a composition for use in a method of decreasing the immunogenicity of the targeting agents. Yet another object of the invention is to provide a plurality of uses for these detection or therapeutic agents.
Upon further study of the specification and appended claims, further objects and advantages of this invention will become apparent to those skilled in the art.
SUMMARY OF THE INVENTION
In its broadest embodiment, the invention provides a composition for use in a method of detecting and/or treating lesions in a patient. The method comprises the steps of (a) parenterally injecting a subject with a targeting composition comprised of (i) a biotin-protein conjugate or (ii) an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced or associated with the targeted lesion, and allowing the protein conjugate to preferentially accrete at the targeted lesion; (b) then, optionally, parenterally injecting a clearing composition comprised of (i) avidin, when the targeting composition is a biotin-protein conjugate, or (ii) biotin, when the targeting composition is an avidin-protein conjugate, and allowing the clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion; (c) parenterally injecting a detection or therapeutic composition comprised of a conjugate of (i) avidin, protein and detection or therapeutic agent, or (ii) biotin, protein and detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and wherein the protein may be the same as the protein of the targeting composition, and allowing the composition to accrete at the targeted lesion; and (d) parenterally injecting, either prior or subsequent to the composition of (c) , another detection or therapeutic composition comprised of (i) avidin conjugated to a detection or therapeutic agent, or (ii)biotin conjugated to a detection or therapeutic agent, wherein the detection or therapeutic agent may be the same as the detection on therapeutic agent of step (c) , and allowing the conjugate to accrete at the targeted lesion, wherein (i) step (d) is optional if a clearing composition has been administered, (ii) the detection or therapeutic compositions of step (c) and (d) containing avidin are administered as the next step after the administration of a composition containing biotin or of a clearing composition containing avidin, (iii) detection or therapeutic compositions of step (c) and (d) containing biotin are administered as the next step after the administration of a composition containing avidin or of a clearing composition containing biotin.
In variations of the above embodiment, the following compositions are used in each step.
In a three-stage embodiment, first the targeting composition comprised of a biotin-protein conjugate is injected, and no clearing composition is administered; then a detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent is injected and then a detection or therapeutic composition comprised of a conjugate of biotin, protein and detection or therapeutic agent is injected.
In a four-step embodiment, a targeting composition comprised of a biotin-protein conjugate is first injected, then a clearing composition comprised of avidin is injected, then a detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent is injected, and, lastly, a detection or therapeutic composition comprised of a conjugate of biotin, protein and detection or therapeutic agent is injected.
In another four-step embodiment, a targeting composition comprised of a biotin-protein conjugate is injected, then a clearing composition comprised of avidin is injected, then a detection or therapeutic composition comprised of a conjugate of biotin, protein and detection or therapeutic agent is injected, and, lastly, another detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent is injected.
In another four-step embodiment, a targeting composition comprised of a bin in-protein conjugate is injected, then a clearing composition comprised of avidin is injected, then a detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent is injected, and, lastly, a detection or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent is injected.
In another three-step embodiment, a targeting composition comprised of a biotin-protein conjugate is injected, then a clearing composition comprised of avidin is injected, and, lastly, a detection or therapeutic composition comprised of a conjugate of biotin, protein and detection or therapeutic agent is injected.
In another four-step embodiment, a targeting composition comprised of a biotin-protein conjugate is injected, then a clearing composition comprised of avidin is injected, then a detection or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent is injected, and, lastly, another detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent is injected.
In another three-step embodiment, a subject is first injected with a targeting composition comprised of an avidin-protein conjugate, then the subject is injected with a detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent, and, lastly, the subject is injected with a detection or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent.
In another four-step embodiment, a targeting composition comprised of an avidin-protein conjugate is injected, then a clearing composition comprised of biotin is injected, then a detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent is injected, and, lastly, a detection or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent is injected. In another four-step embodiment, an avidin-protein conjugate is injected, then a clearing composition comprised of biotin is injected, then a detection or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent is injected, and, lastly, another detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent is injected. In another four-step embodiment, a targeting composition comprised of an avidin-protein conjugate is injected, then a clearing composition comprised of biotin is injected, then a detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent is injected, and, lastly, another detection or therapeutic composition comprised of biotin, protein and detection or therapeutic agent is injected.
In another three-step embodiment, a targeting composition comprised of an avidin-protein conjugate is injected, then a clearing composition comprised of biotin is injected, and, lastly, a detection or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent is injected.
In another four-step embodiment, a targeting composition comprised of an avidin-protein conjugate is injected, then a clearing composition comprised of biotin is injected, then a detection or therapeutic composition comprised of a conjugate of biotin, protein and detection or therapeutic agent is injected, and, lastly, another detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent is injected.
DETAILED DISCUSSION
It has now been found that the use of the compositions disclosed herein in 3- and 4-step procedures of the present invention is more advantageous for selective detection and therapy of lesions than the uses disclosed in the prior art.
In a more preferred embodiment of this invention involving a 3-step approach, a biotinylated targeting antibody or fragment is injected, followed by the application of avidin as a clearing agent. Then, as a third step, instead of administering biotin-conjugated isotope or drug as taught in the prior art, a lesion- targeting antibody or fragment conjugate is administered. The antibody or fragment is either the same as that of the first step or another such targeting antibody or fragment, and is conjugated with biotin and with a detection or therapeutic agent. Using the lesion- targeting antibody or fragment conjugate forms another lattice of complexation of biotin-avidin-biotin, with the added advantage of targeting to the lesion with the antibody or fragment.
The more preferred 4-step embodiments have two basic approaches. In both, the first step is the injection of a biotinylated antibody or fragment and the second step is the injection of an avidin chase. The third step involves the injection of either avidin conjugated with a detection or therapeutic agent, or, alternatively, a biotin conjugated with a detection or therapeutic agent. When the third step uses an avidin conjugate, the fourth step is an injection of a biotinylated anti-lesion antibody or fragment conjugated with a detection or therapeutic agent. When the third step involves biotin conjugated with a detection or therapeutic agent, the fourth step requires the injection of an anti-lesion antibody or fragment conjugated with avidin and with a detection or therapeutic agent.
Each of these 4-step approaches is an improvement, in terms of absolute amount of detection or therapeutic agent delivered and retained at the site of the lesion, as compared to the prior art 2- and 3-step procedures which did not contemplate the use of a biotinylated or avidin-conjugated antibody or fragment bearing additional detection or therapeutic agents for enhancement of the effects as a last step.
Of course, if desired, the sequence can be repeated for additional accumulation of the agents, as needed. Further, the preferred lesion-localizing antibody can be a bispecific or hybrid antibody, whereby at least 2 antibody arms are directed against different epitopes of the same antigen or against different substances associated with the lesion. This is preferred in order to achieve higher levels of accretion and binding in the lesion.
These uses of the compositions of the present invention provide the following improved results over other sequences reported earlier by others: 1. increased binding and retention of primary antibody in the lesion;
2. higher lesion:normal organ (including kidney) ratios;
3. increased targeting of detection and therapeutic agents to the lesion; and
4. improved lesion detection or therapy.
The detection/therapeutic agents used in the present invention can be any or multiples of the following:
A- diagnostic or therapeutic radionuclides (e.g. ,alpha-, beta-, gamma-, positron-, x-ray- and fluorescence-emitters; electron- and neutron-capturing agents) ; B- photoactivated dyes for detection or therapy; C- cytotoxic agents (e.g., drugs, toxins, hormones, cytokines, hormone antagonists, receptor antagonists) ; D- differentiation agents (e.g., vitamins, cytokines, autocrines, certain hormones and drugs) . The compositions of the present invention can be used to detect (either by internal procedures or by external imaging) and/or treat lesions, including cancers, infectious diseases, cardiovascular diseases and other pathological conditions. Internal detection procedures include intraoperative, intravascular or endoscopic, including laparoscopic, techniques, both surgically invasive and non-mvasive.
Avidins are a family of proteins functionally defined by their ability to bind biotin with high affinity and specificity. Avidins are fairly small oligomeric proteins, made up of four identical subunits, each bearing a single binding site for biotin. Avidins can therefore bind up to four moles of biotin per mole of avidin.
Avidins include proteins (a) produced by amphibians, reptiles and avians, which are present in their eggs and known as avidin, and (b) produced by a streptomyces,
Streptomyces avidinii , and known as streptavidin. As used herein "avidin" includes all of the above proteins.
Proteins are known which preferentially bind marker substances that are produced by or associated with lesions. For example, antibodies can be used against cancer-associated substances, as well as against any pathological lesion that shows an increased or unique antigenic marker, such as against substances associated with cardiovascular lesions, such as, vascular clots including thrombi and emboli, myocardial infarctions and other organ infarcts, atherosclerotic plaques; inflammatory lesions; and infectious and parasitic agents. Examples of appropriate applications are provided in the above-referenced Goldenberg patents and applications.
The cancer states include carcinomas, melanomas, sarcomas, neuroblastomas, leukemias, lymphomas, gliomas and myelomas. The infectious diseases include those caused by invading microbes or parasites. As used herein, "microbe" denotes virus, bacteria, rickettsia, mycoplasma, protozoa, fungi and like microorganism-., "parasite" denotes infectious, generally microscopic or very small multicellular invertebrates, or ova or juvenile forms thereof, which are susceptible to antibody-induced clearance or lytic or phagocytic destruction, e.g., malarial parasites, spirochetes and the like, including helminths, while "infectious agent" or "pathogen" denotes both microbes and parasites.
The protein substances useful in the present invention include protein, peptide, polypeptide, glycoprotein, lipoprotein, or the like, e.g. hormones, lymphokines, growth factors, albumin, cytokines, enzymes, immune modulators, receptor proteins, antibodies and antibody fragments.
The protein substance of particular interest in the present invention are antibodies and antibody fragments. By "antibodies and antibody fragments" is meant generally immunoglobulins or fragments thereof that specifically bind to antigens to form immune complexes.
The antibody may be whole immunoglobulin of any class, e.g., IgG, IgM, IgA, IgD, IgE, chimeric or hybrid antibodies with dual or multiple antigen or epitope specificities. It can be a polyclonal antibody, preferably an affinity-purified antibody from a human or an appropriate animal, e.g., a primate, goat, rabbit, mouse or the like. Monoclonal antibodies are also suitable for use in the present invention, and are preferred because of their high specificities. They are readily prepared by what are now considered conventional procedures of immunization of mammals with immunogenic antigen preparation, fusion of immune lymph or spleen cells with an immortal myeloma cell line, and isolation of specific hybridoma clones. More unconventional methods of preparing monoclonal antibodies are not excluded, such as interspecies fusions and genetic engineering manipulations of hypervariable regions, since it is primarily the antigen specificity of the antibodies that affects their utility in the present invention. It will be appreciated that newer techniques for production of monoclonals can also be used, e.g., human monoclonals, interspecies monoclonals, chimeric (e.g. , human/mouse) monoclonals, genetically engineered antibodies and the like.
.Antibody fragments useful in the present invention include F(ab')2, F(ab)2, Fab', Fab, Fv and the like including hybrid fragments. Preferred fragments are Fab', F(ab')2, Fab, and F(ab)2. Also useful are any subfragments retainingthehypervariable, antigen-binding region of an immunoglobulin and having a size similar to or smaller than a Fab' fragment. This will include genetically engineered and/or recombinant proteins, whether single-chain or multiple-chain, which incorporate an antigen-binding site and otherwise function in vivo as targeting vehicles in substantially the same way as natural immunoglobulin fragments. Such single-chain binding molecules known in the art, and are disclosed in U.S.Patent 4,946,778. Fab' antibody fragments may be conveniently made by reductive cleavage of F(ab')2 fragments, which themselves may be made by pepsin digestion of intact immunoglobulin. Fab antibody fragments may be made by papain digestion of intact immunoglobulin, under reducing conditions, or by cleavage of F(ab)2 fragments which result from careful papain digestion of whole immunoglobulin. The fragments may also be produced by genetic engineering.
It should be noted that mixtures of antibodies and immunoglobulin classes can be used, as can hybrid antibodies. Multispecific, including bispecific and hybrid, antibodies and antibody fragments are especially preferred in the present invention for detecting and treating lesions and are comprised of at least two different substantially monospecific antibodies or antibody fragments, wherein at least two of said antibodies or antibody fragments specifically bind to at least two different antigens produced or associated with the targeted lesion or at least two different epitopes or molecules of a marker substance produced or associated with the targeted lesion. Multispecific antibodies and antibody fragments with dual specificities can be prepared analogously to the anti-tumor marker hybrids disclosed in U.S. Pat. No. 4,361,544. Other techniques for preparing hybrid antibodies are disclosed in, e.g.. U.S. Pat. No. 4,474,893 and 4,479,895, and in Milstein et al., Immunol. Today, 5,299(1984).
Preferred are proteins having a specific immunoreactivity to a marker substance of at least 60% and a cross-reactivity to other antigens or non-targeted substances of less than 35%.
As disclosed above, antibodies against tumor antigens and against pathogens are known. For example, antibodies and antibody fragments which specifically bind markers produced by or associated with tumors or infectious lesions, including viral, bacterial, fungal and parasitic infections, and antigens and products associated with such microorganisms have been disclosed, inter alia, in Hansen et al., U.S. Patent 3,927,193 and Goldenberg U.S. Patents 4,331,647, 4,348,376, 4,361,544, 4,468,457, 4,444,744, 4,818,709 and 4,624,846. In particular, antibodies against an antigen, e.g., a gastrointestinal, lung, breast, prostate, ovarian, testicular, brain or lymphatic tumor, a sarcoma or a melanoma, are advantageously used.
A wide variety of monoclonal antibodies against infectious disease agents have been developed, and are summarized in a review by Polin, in Eur. J. Clin. Microbiol., 3(5) :387-398, 1984, showing ready availability. These include monoclonal antibodies (MAbs) against pathogens and their antigens such as the following:
Anti-bacterial Mabs
Streptococcus agalactiae Legionella pneumophilia
Streptococcus pyogenes
Escherichia coli
Neisseria gonorrhosae
Neisseria meningitidis Pneumococcus
Hemophilis influenzae B
Treponema pallidum Lyme disease spirochetes Pseudomonas aeruginosa Mycobacterium leprae Brucella abortus Mycobacterium tuberculosis Tetanus toxin
Anti-viral MAbs
HIV-1, -2, -3
Hepatitis A, B, C, D Rabies virus
Influenza virus
Cytomegalovirus
Herpes simplex I and II
Human serum parvo-like virus Respiratory syncytial virus
Varicella-Zoster virus
Hepatitis B virus
Measles virus
Adenovirus Human T-cell leukemia viruses
Epstein-Barr virus
Murine leukemia virus*
Mumps virus
Vesicular stomatitis virus Sindbis virus
Lymphocytic choriomeningitis virus
Wart virus
Blue tongue virus
Sendai virus Feline leukemia virus*
Reo virus
Polio virus
Simian virus 40*
Mouse mammary tumor virus* Dengue virus
Rubella virus
*=animal virus Anti-protozoan MAbs
Plasmodium falciparυm
Plasmodium vivax
Toxoplasma gondii Trypanosoma rangeli
Trypanosoma cruzi
Trypanosoma rhodesiensei
Trypanosoma brucei
Schistosoma mansoni Schistosoma japanicum
Babesia bovis
Elmeria tenella
Onchocerca volvulus
Leishmania tropica Trichinella spiralis theileria parva
Taenia hydatigena
Taenia ovis
Taenia saginata Echinococcus granulosus
Mesocestoides corti
Antimvcoplasmal MAbs Mycoplasma arthritidis M. hyorhinis M. orale
M. arginini Acholeplasma laidlawii M. salivariu M. pneumoniae
Additional examples of MAbs generated against infectious organisms that have been described in the literature are noted below.
MAbs against the gpl20 glycoprotein antigen of human immunodeficiency virus 1 (HIV-1) are known, and certain of such antibodies can have an immunoprotective role in humans. See, e.g., Rossi et al., Proc. Natl. Acad. Sci. USA, 86:8055-8058, 1990. Other MAbs against viral antigens and viral induced antigens are also known. This shows that proper selection of the epitope can distinguish between a therapeutic and non-therapeutic target.
MAbs against malaria parasites can be directed against the sporozoite, merozoite, schizont and gametocyte stages. Monoclonal antibodies have been generatedagainst sporozoites (circumsporozoite antigen) , and have been shown to neutralize sporozoites in vitro and in rodents (N. Yoshida et al.. Science 207:71-73, 1980) .
Several groups have developed MAbs to T. gondii, the protozoan parasite involved in toxoplasmosis (Kasper et al., J. Immunol. 129:1694-1699, 1982; Ic i., 130:2407-2412, 1983) .
MAbs have been developed against schistosomular surface antigens and have been found to act against schistosomulae in vivo or in vitro (Simpson et al., Parasitology, 83:163-177, 1981; Smith et al., Parasitology, 84:83-91, 1982; Gryzch et al. , J. Immunol., 129:2739-2743, 1982; Zodda et al. , J. Immunol. 129:2326- 2328, 1982; Dissous et al. , J. Immunol., 129:2232-2234, 1982) . Trypanosoma cruzi is the causative agent of Chagas' disease, and is transmitted by blood-sucking reduviid insects. A MAb has been generated that specifically inhibits the differentiation of one form of the parasite to another (epimastigote to trypomastigote stage) in vitro, and which reacts with a cell-surface glycoprotein; however, this antigen is absent from the mammalian (bloodstream) forms of the parasite (Sher et al.. Nature, 300:639-640, 1982).
Suitable MAbs have been developed against most of the microorganisms (bacteria, viruses, protozoa, other parasites) responsible for the majority of infections in humans, and many have been used previously for in vitro diagnostic purposes. These antibodies, and newer MAbs that can be generated by conventional methods, are appropriate for use in the present invention.
Proteins useful for detecting and treating cardiovascular lesions include fibrin-specific proteins, for example, fibrinogen, soluble fibrin, antifibrin antibodies and fragments, fragment E_ (a 60 kDa fragment of human fibrin made by controlled plasmin digestion of crosslinked fibrin) , plasmin (an enzyme in the blood responsible for the dissolution of fresh thrombi) , plasminogen activators (e.g., urokinase, streptokinase and tissue plasminogen activator) , heparin, and fibronectin (an adhesive plasma glycoprotein of 450 kDa) and platelet-directed proteins, for example, platelets, antiplatelet antibodies and antibody fragments, anti- activated platelet antibodies, and anti-activated- platelet factors, which have been reviewed by Koblik et al., Semin. Nucl . Med. , 19:221-237 (1989).
Among the radionuclides useful in the present invention, gamma-emitters, positron-emitters, x-ray emitters and fluorescence-emitters are suitable for localization and/or therapy, while beta- and alpha- emitters and electron- and neutron-capturing agents also can be used for therapy.
Suitable radioisotopes for use in the present invention include: Astatine-211, Iodine-123, Iodine-125, Iodine-126, Iodine-131, Iodine-133, Bismuth-212, Bromine- 77, Indium-Ill, Indium-113m, Gallium-67, Gallium-68, Ruthenium-95, Ruthenium-97, Ruthenium-103, Ruthenium-105, Mercury-107, Mercury-203, Rhenium-186, Rhenium-188, Tellurium-121m, Tellurium-122m, Tellurium-125m, Thulium- 165, Thulium-167, Thulium-168, Technetium-99m, Fluorine- 18, Silver-Ill, Platinum-197, Palladium-109, Copper-67, Phosphorus-32, Phosphorus-33, Yttri --.-90, Scandium-47, Samarium-153, Lutetium-177, Rhodium-105, Praseodymium- 142, Praseodymium-143, Terbium-161, Holmium-166, Gold- 199, Cobalt-57, Cobalt-58, Chromium-51, Iron-59, Selenium-75, Thallium-201, and Ytterbium-169. Preferably the radioisotope will emit in the 10 - 5,000 kev range. more preferably 50 - 1,500 kev, most preferably 50 - 500 kev.
Isotopes preferred for external imaging include:Iodine-123, Iodine-131, Indium-Ill, Gallium-67, Ruthenium-97, Technetium-99m, Cobalt-57, Cobalt-58,
Chromium-51, Iron-59, Selenium-75, Thallium-201, and
Ytterbium-169.
Isotopes most preferred for internal detection include: Iodine-125, Iodine-123, Iodine-131, Indium-Ill, Technetium-99m and Gallium-67.
Isotopes preferred for therapeutic use include: Iodine-125, Iodine-131, Rhenium-186, Rhenium-188, Silver- Ill, Platinum-197, Palladium-109, Copper-67, Phosphorus- 32, Phosphorus-33, Yttrium-90, Scandium-47, Samarium-153,
Lutetium-177, Rhodium-105, Praseodymium-142,
Praseodymium-143, Terbium-161, Holmium-166, andGold-199.
Many drugs and toxins are known which have cytotoxic effects on cells. They are to be found in compendia of drugs and toxins, such as the Merck Index, Goodman and Gilman, and the like, and in the references cited above. Any such drug can be conjugated to or loaded onto the antibody by conventional means well know in the art, and illustrated by analogy to those described above. The present invention also contemplates dyes used, for example, in photodynamic therapy, conjugated to proteins, biotin or avidin and used in conjunction with appropriate nonionizing radiation.
The use of light and porphyrins in the present invention is also contemplated and their use in cancer therapy is readily available to one of ordinary skill in the are, as reviewed by van den Bergh (Chemistry in Britain, May 1986.- Vol. 22, pp. 430-437).
Examples of known cytotoxic agents useful in the present invention are listed in Goodman et al., "The Pharmacological Basis of Therapeutics," Sixth Edition, A.G. Gilman et al, eds./ Macmillan Publishing Co. New York, 1980. These include taxol, nitrogen mustards, such as mechlorethamine, cyclophosphamide, melphalan, uracil mustard and chlorambucil; ethylenimine derivatives, such as thiotepa; alkyl sulfonates, such as busulfan; nitrosoureas, such as carmustine, lomustine, semustine and streptozocin; triazenes, such as dacarbazine; folic acid analogs, such as methotrexate; pyri idine analogs, such as fluorouracil, cytarabine and azaribine; purine analogs, such as mercaptopurine and thioguanine; vinca alkaloids, such as vinblastine and vincristine; antibiotics, such as dactinomycin, daunorubicin, doxorubicin, bleomycin, mithramycin and mitomycin; enzymes, such as L-asparaginase; platinum coordination complexes, such as cisplatin; substituted urea, such as hydroxyurea; methyl hydrazine derivatives, such as procarbazine; adrenocortical suppressants, such as mitotane; hormones and antagonists, such as adrenocortisteroids (prednisone) , progestins (hydroxyprogesterone caproate, medroprogesterone acetate and megestrol acetate) , estrogens (diethylstilbestrol and ethinyl estradiol) , antiestrogens (tamoxifen) , and androgens (testosterone propionate and fluoxymesterone) .
Drugs that interfere with intracellular protein synthesis can also be used in the methods of the present invention; such drugs are known to these skilled in the art and include puromycin, cycloheximide, and ribonuclease.
Toxins can also be used in the methods of the present invention. Toxins useful as therapeutics are known to those skilled in the art and include plant and bacterial toxins, such as, abrin, alpha toxin, diphtheria toxin, exotoxin, gelonin, pokeweed antiviral protein, ricin, and saporin.
Toxins in their native form require a minimum of three different biochemical functions to kill cells: a cell binding function, a cytotoxic function, and a function to translocate the toxic activity into the cells.
The modified toxins useful in the present invention differ from native toxins in that the domain providing the cell binding function of the native toxin is nonfunctioning because the domain is missing partially or totally. Other therapeutic agents useful in the present invention include anti-DNA, anti-RNA, anti-protein and anti-chromatin cytotoxic or antimicrobial agents.
The proteins useful in the present invention may be labeled or conjugated by a variety of methods known in the art. Many of these methods are disclosed in the above-referenced U.S. Patents and Patent Applications. See also, Rayudu, OP. cit. : and Childs et al., J. Nuc. Med.. 26. 293(1985). Any conventional method of radiolabeling which is suitable for labeling isotopes for in vivo use will be generally suitable for labeling detection agents according to the present invention.
The avidin/streptavidin, biotin or proteins may be conjugated to therapeutic agents such as drugs, toxins, boron addends, isotopes, fluorescent dyes activated by nonionizing radiation, hormones, autocrines, cytokines, cytoprotective agents, etc., by methods known to those skilled in the art. US Patent 5,057,313, Shih et al, teaches one such method.
Other examples are conjugating avidin/streptavidin to (a) iodine by the chloramine-T or Bolton-Hunter procedures, (b) technetium/rhenium by procedures described by Griffiths et al. (Cancer Res. 51:4594, 1991) or Fritzberg et al. (U.S. Pat. No. 5,120,526) and (c) metallic nuclides through bifunctional chelating agents as described by Meares et al. (Br. J. Cancer 62:21, 1990) . Additionally avidin/streptavidin/biotin can be bound to dendrimers by procedures described for amino- containing proteins as described by Hnatowich et al. (J. Nucl. Med. 28:1294, 1987). Biotin can be readily conjugated to proteins (including antibodies and their fragments) via the proteins* lysine and cysteine residues, and, if available, their oxidized carbohydrate groups. The detection or therapeutic agents may be treated by methods, known to those skilled in the art, to permit the agents to be more easily conjugated to biotin, avidin/streptavidin or targeting protein as required. Loading of drugs onto a carrier, as disclosed in U.S. Patent 5,057,313, will depend upon the potency of the drug, the efficiency of the antibody targeting and the efficacy of the conjugate once it reaches its target. In most cases, it is desirable to load at least 20, preferably 50 and often 100 or more molecules of a drug on a carrier. The ability to partially or completely detoxify a drug as a conjugate, while it is circulation, can reduce systemic side effects of the drug and permit its use when systemic administration of the unconjugated drug would be unacceptable.
Toxins will often be less heavily loaded than drugs, but it will still be advantageous to load at least 1, preferably 5, and in some cases 10 or more molecules of toxin on a carrier and load at least one carrier chain on the antibody for targeted delivery.
In addition to conjugating radioisotopes to biotin (or to streptavidin) for targeting to tumors (or other lesions) , it is possible to conjugate drugs to avidin, for example via a dextran spacer molecule (Schechter et al.. Int. J. Cancer 48:167, 1991) for delivery of a cytotoxic agent to tumors in animals.
Methods for treating toxins and, in particular, modified Psuedomonas exotoxins, are well known in the art and are disclosed, for example, in Batkra et al. ,Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 8545-8549, 1989; Seetharam et al., J. Biol. Chem., Vol 266, no. 26, pp. 17376-17381, 1991; and Pastan et al., and U.S. Patent 4,892,827.
When conjugating the foregoing quantity of antibody or antibody fragment, the amount of drug or toxin is generally about 0.25 to 5 times, preferably 1-3 times, the amount of antibody or antibody fragment, and the time of reaction is about 10 to 120 minutes, preferably 30-90 minutes .
A physiological solution of the protein conjugate is advantageously metered into sterile vials, e.g., at a unit dosage of about 1.0 - 500 mg protein conjugate/vial, and the vials are either stoppered, sealed and stored at low temperature, or lyophilized, stoppered, sealed and stored. Variations and modifications of these formulations will be readily apparent to the ordinary skilled artisan, as a function of the individual needs of the patient or treatment regimen, as well as of variations in the form in which the radioisotopes may be provided or may become available.
The present invention includes uses of the compositions wherein there is a reduction of the immunogenicity of (a) avidin (b) the therapeutic agent moiety of a conjugate, e.g., the toxin, or (c) the targeting composition, by coupling the immunogenic agent with a carbohydrate polymer or polyol groups. Examples of useful carbohydrates or polyol groups include dextran, polysaccharides, polyethylene glycol (PEG) , and the like.
The use of a dextran or another polymer for attachment of the therapeutic agents to avidin, or a dextran or another polymer coupled directly to avidin or streptavidin is desirous to decrease the immunogenicity of the conjugates involving avidin. This then permits repeated applications of avidin alone or as a conjugate, in the treatment courses. If the avidin used in the clearing composition is so coupled then more time may be needed for the clearing composition to fulfill its functions.
In an embodiment of the 3-step improved detection or therapeutic protocol of the present invention, the biotinylated or avidin (streptavidin) lesion-targeting protein can be injected parentally, usually at a protein dose of 0.5 to 50 mg, more preferably within a dose range of 1.0 to 20.0 mg, and still more preferably at 2.0 to 10.0 mg. This can be administered as a single injection or in divided doses. After 1-5 days, more preferably at less than 2 days and even at less than 1 day when the first agent involves a small and rapidly targeting molecule, such as an antibody fragment or subfragment, a dose of unlabeled clearing agent, such as 2.0 to 200.0 mg avidin (more preferably about a ratio of 2.5:1 to 10:1 of avidin to biotinylated protein) when a biotinylated lesion-targeting protein is used as the first agent, is administered parenterally. The clearing agent can be given as a single injection or in divided doses, wherein administering the clearing agent in 2 doses is preferred in certain circumstances. The third step involves injection of the biotinylated (or avidin-conjugated) lesion-targeting protein, as in the first step, but conjugated to a detection or therapeutic agent. The lesion-targeting protein can be identical to that of the first step, or another protein capable of similarly targeting the lesion, such as a second targeting antibody. The third step's reagents can be administered parenterally within 24 hrs of the 2nd step, but also at up to 3 days later. In one detection embodiment, the third step involves 111-In conjugated to biotin attached to a lesion-targeting antibody or antibody fragment. Within 24 hrs of the last injection, more preferably within 4 hrs, planar and single-photon emission computed tomography scans are made with a gamma camera equipped with the appropriate collimator and selecting the appropriate energy windows for the detection isotope being used, such as 173 keV and 247 keV for 111-In.
In an embodiment of a 4-step detection or therapy protocol of the present invention, the biotinylated or avidin (streptavidin) lesion-targeting protein can be injected parenterally, usually at a protein dose of 2 to 200 mg, more preferably within a dose range of 5 to 50 mg, more preferably at 2.0 to 10.0 mg. This can be administered as a single or as divided injections. After 1-5 days, more preferably at less than 2 days and even at less than 1 day when the first agent involves a small and rapidly targeting molecule, such as an antibody fragment or subfragment, a dose of unlabeled clearing agent, such as 2.5- to 10-times the dose of the first step's protein (which can be determined also by measuring the amount of first agent's protein circulating in the blood at the time of the second step's injection) , is given parenterally. The longer the delay after the first step, the lower the amount (and ratio) of clearing agent given. The clearing agent can be given as a single injection or in divided doses, dividing the administration of the clearing agent into at least 2 doses may be preferable, usually within a short period, such as within 2 hrs. In the third step of one embodiment of the invention, a dose of 2 to 200 mg protein, more preferably 5 to 50 mg, of biotin conjugated with a detection or therapeutic agent, as appropriate, is administered parenterally either as a single dose or in divided doses. A fourth step involves the parenteral administration of avidin (or streptavidin) conjugated to a lesion-targeting agent, which can be the same or different from the first lesion-targeting agent, to which a detection or therapeutic agent, as appropriate, is also attached.
In another embodiment, the third step can involve the biotinylated lesion-targeting protein conjugated with a detection or therapeutic agent, as appropriate, and the fourth step the detection or therapeutic agent, as appropriate, conjugated to avidin (or streptavidin) . The third step's reagents can be administered within 24 hrs of the 2nd step, but also at up to 7 days or more later, depending upon the targeting time and clearance involving the first two steps. The fourth step can be initiated within 24 hrs of the third step, but also up to 7 days or more later.
Routes of administration include intravenous, intraarterial, intrapleural, intraperitoneal, intrathecal, subcutaneous or by perfusion.
An application of the lesion-specific or lesion- associated protein disclosed hereinabove is for magnetic resonance imaging (mri) . In this case, for example, a suitably radiolabeled antibody/fragment or an antibody/fragment bearing a mr image enhancing agent is administered with the intention of obtaining an image of the lesion. The uses of compositions in methods according to the invention can be practiced either with scintigraphic or magnetic resonance imaging agents. A combination of these imaging agents can also be used, although this requires more complex instrumentation and data processing.
Scintigraphic imaging according to the method of the invention is effected by obtaining a scintigram of the lesion of interest.
The scintigram is normally taken by a gamma imaging camera having one or more windows for detection of energies in the 50-500 keV range. Use of radioisotopes with higher energy, beta, or positron emissions would entail use of imaging cameras with the appropriate detectors, all of which are conventional in the art. The scintigraphic data can be stored in a computer for later processing.
Methods useful for internal detection and/or treatment of tumors and/or other lesions are readily available to those skilled in the art, and are disclosed, for example, in U.S. Patent 4,782,840; U.S.Patent 4,932,412; and copending U.S. Application 07/879,857. The uses of compositions according to the present invention can enhance the methods disclosed in these references. Magnetic resonance imaging (mri) is effected in an analogous manner to scintigraphic imaging except that the imaging agents will contain magnetic resonance (mr) enhancing species rather than radioisotopes. It will be appreciated that the magnetic resonance phenomenon operates on a different principle from scintigraphy. Normally, the signal generated is correlated with the relaxation times of the magnetic moments of protons in the nuclei of the hydrogen atoms of water molecules in the region to be imaged. The magnetic resonance image enhancing agent acts by increasing the rate of relaxation, thereby increasing the contrast between water molecules in the region where the imaging agent accretes and water molecules elsewhere in the body. However, the effect of the agent is to decrease both Tj and T2, the former resulting in greater contrast while the latter results in lesser contrast. Accordingly, the phenomenon is concentration-dependent, and there is normally an optimum concentration of a paramagnetic species for maximum efficacy. This optimal concentration will vary with the particular agent used, the locus of imaging, the mode of imaging, i.e., spin-echo, saturation-recovery, inversion-recovery and/or various other strongly 1_- dependent or T2-dependent imaging techniques, and the composition of the medium in which the agent is dissolved or suspended. These factors, and their relative importance are known in the art. See, e.g., Pykett, Scientific American. 246. 78(1982); Runge et al.. Am. J. Radiol.. 141. 1209(1983).
The mr image enhancing agent must be present in sufficient amounts to enable detection by an external camera, using magnetic field strengths which are reasonably attainable and compatible with patient safety and instrumental design. The requirements for such agents are well known in the art for those agents which have their effect upon water molecules in the medium, and are disclosed, inter alia, in Pykett, op. cit. , and Runge et al. , op., cit. Preparation of protein, biotin or avidin/streptavidin (molecule) conjugated to a magnetic resonance image enhancing agent can be effected by a variety of methods. In order to load a molecule with a large number of paramagnetic ions, it may be necessary to react it with a reagent having a long tail to which are attached a multiplicity of chelating groups for binding the ions. Such a tail can be a polymer such as a polylysine, polysaccharide, or other derivatized or derivatizable chain having pendant groups to which can be bound chelating groups such as, e.g., ethylenediaminetetra- acetic acid (EDTA) , diethylenetriaminepentaacetic acid (DTPA) , porphyrins, polya ines, crown ethers, bis-thio- semicarbazones, polyoximes, and like groups known to be useful for this purpose. The chelate is normally linked to the molecule by a group which enables formation of a bond to the molecule with minimal loss of immunoreactivity and minimal aggregation and/or internal cross-linking. Other, more unusual, methods and reagents for conjugating chelates to antibodies are disclosed in U.S. Patent 4,824,659 to Hawthorne, entitled "Antibody Conjugates", issued April 25, 1989.
MRI contrast agents are well known in the art and include, for example. Gadolinium, Iron, Manganese, Rhenium, Europium, Lanthanium, Holmium, and Ferbium.
The mr scans are stored in a computer and the images processed analogously to the scintigraphic data.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. In the following examples, all temperatures are set forth uncorrected in degrees Celsius; unless otherwise indicated, all parts and percentages are by weight.
Accordingly, these embodiments constitute improved compositions and uses thereof for amplification of protein, especially antibody and antibody fragments, targeting for detecting and therapy of cancer and other pathological condition--*
EXAMPLES
Example 1 - Conjugating Antibody or Antibody Fragment to Biotin via Lvsine. An antibody or antibody fragment at a concentration of 1-20 mg/ml in a non-amine containing buffer (e.g. ,borate, phosphate, etc.), at a suitable concentration (0.05-0.5 M) , at a slightly elevated pH (7.0-9.5), is mixed with a 1-100 molar excess of the activated ester (succini ide or sulfosuccinimide are preferred) of D-biotin or D-biotin incorporating a spacer arm (such as succinimido-6-[biotinamido]hexanoate) . A co-solvent, such as dimethylformamide (DMF) or dimethylsulfoxide (DMSO) , may be added to provide a final concentration of up to 20% to facilitate reactant solubility. The reaction solution is stirred for 1-24 hours and kept at a temperature of 4°C to 37βC. At the end of the reaction period, the modified protein is separated from unbound biotin and other low molecular weight contaminants by size-exclusion chromatography and/or dialysis.
Example 2 - Conjugating Antibody or Antibody Fragment to Biotin via Cvsteine.
An antibody or antibody fragment at a concentration of 5-20 mg/ml in 0.1-0.5 M tris buffer, pH 8.7, is made 0.5-5 mg/ml in 2-mercaptoethanol. The reaction solution is let stand 5-120 min. at a temperature of 4°-37°C. The reduced protein is separated from unreacted thiol by size-exclusion chromatography in 50 mM acetate buffer, pH 4.5. Protein concentration and the number of thiol groups per antibody molecule may be determined at this time. The reduced antibody at a concentration of 1-20 mg/ml in a non-amine containing buffer (e.g., phosphate) at a neutral pH (5.0-7.0) is mixed with a 1-100 molar excess of biotin-maleimide (N-biotinyl-N-[6-maleimido hexanoyl]hydrazide) (Sigma Chem. Co) . A co-solvent, e.g., DMF or DMSO, may be added to provide a final concentration of up to 20% to facilitate reactant solubility. The reaction solution is stirred for 1-24 hours at a temperature between 4-37βC. At the end of the reaction period, the biotinylated protein is separated from unbound biotin and other low molecular weight contaminants by size-exclusion chromatography and/or dialysis.
Example 3 - Conjugating Antibody or Antibody Fragments to Biotin via a Carbohydrate.
Antibody at a concentration of 1-20 mg/ml is treated with sodium metaperiodate to a final concentration of 0.1-10 mg/ml in phosphate buffered saline at room temperature for 1-4 hours. Ethylene glycol is added to decompose the remaining periodate. The oxidized IgG is purified from low molecular weight contaminants by size- exclusion chromatography in phosphate buffer. The oxidized antibody (1-20 mg/ml) is reacted with a 1-100 molar excess of biotin-hydrazide (Pierce Chemical Co.) in a non-amine buffer (e.g., phosphate, carbonate, etc.) at neutral pH (5.0-8.0) for 1-48 hours at 4-37°C. After the optimum time for coupling, the formed hydrazones are reduced by the addition of sodium cyanoborohydride with pH adjustment to >7. The biotinylated antibody is purified by size-exclusion chromatography and/or dialysis.
Example 4 - Conjugating Antibody or Antibody Fragments to Biotin via addended Thiol Groups An antibody or antibody fragment at a concentration of 1-20 mg/ml in a non-amine containing buffer (e.g., borate, carbonate, etc.) at a suitable concentration (0.05-0.5M) and pH (7-10) is mixed with a 1-100 molar excess of 2-iminothiolane hydrochloride (Pierce Chemical Co.). The reaction mixture is made 1-100 mM in EDTA to help prevent disulfide bond formation and held at 4-37° for from 1-4 hours. The modified protein is purified by size-exclusion chromatography in a neutral to slightly acidic buffer (e.g., acetate, citrate, etc.) pH 5.0-7.0. The purified sulfhydryl substituted antibody (1-20 mg/ml) is mixed with a 1-100 molar excess of biotin maleimide. A co-solvent, e.g. , DMF or DMSO, may be added to a final concentration of up to 20% to facilitate reactant solubility. The reaction solution is stirred for 1-24 hours at a temperature between 4-37βC. At the end of the reaction period, the biotinylated protein is separated from unbound biotin and other low molecular weight contaminants by size-exclusion chromatography and/or dialysis.
Example 5 - Conjugating Biotin and Fab' Fragments
An antibody F(ab')2 fragment (obtained by pepsin digestion of the intact antibody) at a concentration of 5-20 mg/ml in phosphate buffer at pH 6-8 is treated with a freshly prepared solution of L-cysteine to give a final cysteine concentration of 1-50 mg/ml. The reaction is allowed to proceed for 1-4 hours at 25-37βC. At the end of this period, the Fab' fragment is purified from low molecular weight contaminants by size-exclusion chromatography in an acidic buffer (e.g., acetate, etc.) at pH 4.0-6.0. The Fab' fragment is reacted with a 1-100 molar excess of biotin-maleimide at pH 5.0-7.0. A co- solvent, e.g., DMF or DMSO, may be added to a final concentration of up to 20% to facilitate reactant solubility. The reaction is stirred for 1-24 hours at a temperature between 4-37βC. At the end of the reaction period, the biotinylated antibody fragment is separated from unbound biotin and other low molecular weight contaminants by size-exclusion chromatography and/or dialysis.
Example 6 - Determination of Extent of Biotinylation of Proteins
A small amount of biotinylated antibody is heated to 56° in 0.1M phosphate buffer for 10 minutes and enzymatically digested with small volumes of 1% pronase (Sigma Chemical Co.). The digestion is allowed to proceed overnight. The digest is analyzed with a 10 uM solution of avidin saturated with a 100 uM solution of 2- (4'-hydroxyazobenzene)-benzoic acid (HABA) in 0.1M phosphate buffer, pH 7.0. The avidin-HABA solution is titrated with increasing volumes of digested biotinylated antibody as well as a standard biotin solution containing 1-10 mM of biotin. The change in absorbance at 500 nM for each is determined, and the concentration of biotin in the pronase digested biotinylated antibody calculated from reference to the standard curve of the titration of biotin with avidin-HABA.
Example 7 - Cancer Imaging with Three-Step Procedure
A patient diagnosed by sigmoidoscopy to have a colonic neoplasm is injected i.v. with 1.0 mg. of a biotinylated MN-14 monoclonal antibody IgG against carcinoembryonic antigen (CEA) . Two days later, 5 mg of unlabeled avidin (in two divided doses, 20 min apart) is injected i.v. The next day, 1 mg of biotinylated Mu-9 antibody IgG against colon-specific antigen-p (CSAp) labeled with 111-In (4 mCi) is injected i.v. The patient is scanned with a gamma camera 2 hrs later, and a focus of increased radioactivity is detected in the region of the sigmoid colon, in agreement with the sigmoidoscopy findings.
Example 8 - Atherosclerotic Imaging with Three-Step Procedure
A patient with suspected atherosclerotic plaques in various arteries is injected i.v. with 2.0 mg of the biotinylated LL1 monoclonal antibody F(ab')2 against macrophage. One day later, 6 mg of unlabeled avidin (in two divided doses, 15 min apart) is injected i.v. One day later, 1 mg of biotinylated LL1 IgG conjugated with 5 mCi of 111-In is injected i.v., and the patient scanned with a gamma camera 3 hours later. Foci of abnormal radioactivity is found in a tibial artery, the abdominal aorta, and possibly in a right cerebral vessel. Example 9 - Cancer Radioimmunotherapy with a Four-Step Procedure
A patient with several small colonic carcinoma metastases to the liver is injected i.v. with a dose of 10 mg of a first composition comprised of biotinylated MN-14 anti-CEA IgG monoclonal antibody. Two days later, a clearing composition of 25 mg avidin is injected i.v. (in two divided doses, 30 min apart) . After another 2 days, a dose of 10 mg of a second composition of biotin having 25 mCi 90-Y is injected i.v. Two weeks later, a second therapy dose of a third composition of 20 mCi 90-Y conjugated to avidin-labeled MN-14 anti-CEA IgG (10 mg) is given i.v. Based upon liver CT scans and plasma CEA titers performed 8 weeks later, significant regression of the liver tumor lesions is observed.
Figure imgf000035_0001
Procedure
A patient with a right lung adenocarcinoma is injected with biotinylated "RS7" anti-lung-cancer IgG i.v. Four days later, avidin is injected i.v. (in two divided doses, 60 minutes apart) . After another 2 days, a dose of biotinylated RS7 conjugated with aminodextran- doxorubicin, according to the methods described in the Shih patent (USP 4,699,784), is administered i.v. Five days later, a dose of streptavidin conjugated with aminodextran-doxorubicin is administered i.v. Four weeks later, chest CT indicates that the right lung lesion is decreased in size by about 50 percent.
The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
From the foregoing descriptions, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims

1. Use of a composition comprising:
(A) a targeting composition comprising (i) a biotin-protein conjugate or (ii) an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion;
(B) optionally, a clearing composition comprising (i) avidin, when the targeting composition is a biotin-protein conjugate, or
(ii) biotin, when the targeting composition is a avidin-protein conjugate;
(C) a detection or therapeutic composition comprising a conjugate of
(i) avidin, protein and a detection or therapeutic agent, or
(ii) biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; and
(D) optionally, another detection or therapeutic composition comprising
(i) avidin conjugated to a detection or therapeutic agent, or
(ii)biotin conjugated to a detection or therapeutic agent; in a method of detecting or treating targeted lesions in a patient, wherein, in the method, the patient is injected parenterally with:
(a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion;
(b) then, optionally, clearing composition (B) , and said composition is allowed to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion;
(c) detection or therapeutic composition (C) , and said composition is allowed to accrete at the targeted lesion; and
(d) either prior or subsequent to composition (C) , detection or therapeutic composition (D) , and the conjugate of said composition (D) is allowed to accrete at the targeted lesion; wherein
(i) step (d) is optional if a clearing composition
(B) has been administered,
(ii) the detection or therapeutic compositions (C) and (D) of steps (c) and (d) containing avidin are administered as the next step after the administration of a composition containing biotin or of a clearing composition containing avidin, and (iii) the detection or therapeutic compositions (C) and (D) of steps (c) and (d) containing biotin are administered as the next step after the administration of a composition containing avidin or of a clearing composition containing biotin.
2. The use of a composition according to claim 1, wherein the composition comprises:
(A) a targeting composition comprising a biotin- protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion; (B) a detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent; and
(C) a detection or therapeutic composition comprised of a conjugate of biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; in a method for detecting or treating targeted lesions in a patient, wherein, in the method, the patient is injected parenterally with: (a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion;
(b) then, detection or therapeutic composition (B) , and the conjugate of said composition (B) is allowed to accrete at the targeted lesion; and
(c) then, detection or therapeutic composition (C) , and said composition (C) is allowed to accrete at the targeted lesion.
3. The use of a composition according to claim 1, wherein the composition comprises:
(A) a targeting composition comprised of a biotin- protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion; (B) a clearing composition comprised of avidin;
(C) a detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent; and
(D) a detection or therapeutic composition comprised of a conjugate of biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; in a method for detecting or treating targeted lesions in a patient, wherein, in the method, the patient is injected parenterally wjth:
(a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion;
(b) then, clearing composition (B) , and said composition (B) is allowed to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion;
(c) then, detection or therapeutic composition (C) , and the conjugate of said composition (C) is allowed to accrete at the targeted lesion; and
(d) then, detection or therapeutic composition (D) , and said composition (D) is allowed to accrete at the targeted lesion.
4. The use of a composition according to claim 1, wherein the composition comprises:
(A) a targeting composition comprising a biotin- protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion;
(B) a clearing composition comprised of avidin;
(C) a detection or therapeutic composition comprised of a conjugate of biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; and
(D) another detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent; in a method for detecting or treating targeted lesions in a patient, wherein, in the method, a patient is injected parenterally with
(a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion;
(b) then, clearing composition (B) , and said composition (B) is allowed to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion;
(c) then, detection or therapeutic composition (C) , and said composition (C) is allowed to accrete at the targeted lesion; and
(d) then, detection or therapeutic composition (D) , and the conjugate of said composition (D) is allowed to accrete at the targeted lesion.
5. The use of a composition according to claim 1, wherein the composition comprises:
(A) a targeting composition comprising a biotin- protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion;
(B) a clearing composition comprised of avidin;
(C) a detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent; and
(D) another detecting or therapeutic composition comprised of a conjugate of avidin, protein and detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; in a method for detecting or treating targeted lesions in a patient, wherein, in the method, a patient is injected parenterally with: (a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion;
(b) then, clearing composition (B) , and said composition (B) is allowed to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion;
(c) then, detection or therapeutic composition (C) , and the conjugate of said composition (C) is allowed to accrete at the targeted lesion; and
(d) then, detection or therapeutic composition (D) , and said composition (D) is allowed to accrete at the targeted lesion.
6. The use of a composition according to claim 1, wherein the composition comprises:
(A) a targeting composition comprising a biotin- protein conjugate, wherein the protein preferentially binds to a marker substance produced or associated with the targeted lesion;
(B) a clearing composition comprised of avidin; and
(C) a detection or therapeutic composition comprised of a conjugate of biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; in a method for detecting or treating targeted lesions in a patient, wherein, in the method, the patient is parenterally injected with:
(a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion;
(b) then, clearing composition (B) , and said composition (B) is allowed to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion; and
(c) then, detection or therapeutic composition (C) , and said composition (C) is allowed to accrete at the targeted lesion.
7. The use of a composition according to claim l, wherein the composition comprises:
(A) a targeting composition comprising a biotin- protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion; (B) a clearing composition comprised of avidin; (C) a detection or therapeutic composition comprised of a conjugate of avidin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; and
(D) another detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent; in a method for detecting or treating targeted lesions in a patient, wherein, in the method, the patient is injected parenterally with:
(a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion;
(b) then, clearing composition (B) , and said composition (B) is allowed to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion;
(c) then, detection or therapeutic composition (C) , and said composition (C) is allowed to accrete at the targeted lesion; and
(d) then, detection or therapeutic composition (D) , and the conjugate of said composition (D) is allowed to accrete at the targeted lesion.
8. The use of a composition according to claim 1, wherein the composition comprises:
(A) a targeting composition comprising an avidin- protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion;
(B) a detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent; and
(C) a detection or therapeutic composition comprised of a conjugate of avidin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; in a method for detecting or treating targeted lesions in a patient, wherein, in the method, the patient is parenterally injected with:
(a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion;
(b) then, detection or therapeutic composition (B) , and the conjugate of said composition (B) is allowed to accrete at the targeted lesion; and
(c) then, detection or therapeutic composition (C) , and said composition (C) is allowed to accrete at the targeted lesion.
9. The use of a composition according to claim 1, wherein the composition comprises:
(A) a targeting composition comprising an avidin- protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion;
(B) a clearing composition comprised of biotin;
(C) a detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent; and
(D) a detection or therapeutic composition comprised of a conjugate of avidin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; in a method for detecting or treating targeted lesions in a patient, wherein, in the method, the patient is parenterally injected with:
(a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion;
(b) then, clearing composition (B) , and said composition (B) is allowed to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion;
(c) then, detection or therapeutic composition (C) , and the conjugate of said composition (C) is allowed to accrete at the targeted lesion; and (d) then, detection or therapeutic composition (D) , and said composition (D) is allowed to accrete at the targeted lesion.
10. The use of a composition according to claim 1, wherein the composition comprises: (A) a targeting composition comprising an avidin- protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion;
(B) a clearing composition comprised of biotin; (C) a detection or therapeutic composition comprised of a conjugate of avidin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; and
(D) another detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent; in a method for detecting or treating targeted lesions in a patient, wherein, in the method, the patient is parenterally injected with:
(a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion; (b) then, clearing composition (B) , and said composition (B) is allowed to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion;
(c) then, detection or therapeutic composition (C) , and said composition (C) is allowed to accrete at the targeted lesion; and
(d) then, detection or therapeutic composition (D) , and the conjugate of said composition (D) is allowed to accrete at the targeted lesion.
11. The use of a composition according to claim 1, wherein the composition comprises:
(A) a targeting composition comprising an avidin- protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion; (B) a clearing composition comprised of biotin;
(C) a detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent; and
(D) a detection or therapeutic composition comprised of a conjugate of biotin, protein and detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; in a method for detecting or treating targeted lesions in a patient, wherein, in the method, the patient is parenterally injected with:
(a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion;
(b) then, clearing composition (B) , and said composition (B) is allowed to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion;
(c) then, detection or therapeutic composition (C) , and the conjugate of said composition (C) is allowed to accrete at the targeted lesion; and
(d) then, detection or therapeutic composition (D) , and said composition (D) is allowed to accrete at the targeted lesion.
12. The use of a composition according to claim 1, wherein the composition comprises:
(A) a targeting composition comprising an avidin- protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion;
(B) a clearing composition comprised of biotin; and
(C) a detection or therapeutic composition comprised of a conjugate of avidin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; in a method for detecting or treating targeted lesions in a patient, wherein, in the method, the patient is parenterally injected with:
(a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion;
(b) then, clearing composition (B) , and said composition (B) is allowed to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion; and
(c) then, detection or therapeutic composition (C) , and said composition (C) is allowed to accrete at the targeted lesion.
13. The use of a composition according to claim l, wherein the composition comprises:
(A) a targeting composition comprising an avidin- protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion;
(B) a clearing composition comprised of biotin;
(C) a detection or therapeutic composition comprised of a conjugate of biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of said targeting composition (A) ; and
(D) another detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent; in a method for detecting or treating targeted lesions in a patient, wherein, in the method, the patient is parenterally injected with: (a) targeting composition (A) , and the protein conjugate of said composition (A) is allowed to preferentially accrete at the targeted lesion;
(b) then, clearing composition (B) , and said composition (B) is allowed to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion;
(c) then, detection or therapeutic composition (C) , and said composition (C) is allowed to accrete at the targeted lesion; and
(d) then, detection or therapeutic composition (D) , and the conjugate of said composition (D) is allowed to accrete at the targeted lesion.
14. A method of detecting or treating targeted lesions in a patient, the method comprising the steps of:
(a) parenterally injecting a subject with a targeting composition comprised of
(i) a biotin-protein conjugate or (ii) an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially accrete at said targeted lesion;
(b) then, optionally, parenterally injecting a clearing composition comprised of
(i) avidin, when the targeting composition is a biotin-protein conjugate, or
(ii) biotin, when the targeting composition is a avidin-protein conjugate, and allowing said clearing composition to substantially clear the targeting composition from non- targeted sites and to bind to the targeting composition accreted at said targeted lesion;
(c) parenterally injecting a detection or therapeutic composition comprised of a conjugate of
(i) avidin, protein and a detection or therapeutic agent, or
(ii) biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing said detection or therapeutic composition to accrete at said targeted lesion;
(d) parenterally injecting, either prior or subsequent to the composition of (c) , another detection or therapeutic composition comprised of
(i) avidin conjugated to a detection or therapeutic agent, or
(ii)biotin conjugated to a detection or therapeutic agent, and allowing the conjugate to accrete at said targeted lesion; wherein
(i) step (d) is optional if a clearing composition has been administered,
(ii) the detection or therapeutic compositions of steps (c) and (d) containing avidin are administered as the next step after the administration of a composition containing biotin or of a clearing composition containing avidin,
(iii) the detection or therapeutic compositions of steps (c) and (d) containing biotin are administered as the next step after the administration of a composition containing avidin or of a clearing composition containing biotin.
15. The method of claim 14 for detecting or treating targeted lesions in a patient, the method comprising the steps of:
(a) parenterally injecting a subject with a targeting composition comprised of a biotin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially accrete at said targeted lesion;
(b) then, parenterally injecting a detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent, and allowing the conjugate to accrete at said targeted lesion; and
(c) then, parenterally injecting a detection or therapeutic composition comprised of a conjugate of biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing the composition to accrete at said targeted lesion.
16. The method of claim 14 for detecting or treating targeted lesions in a patient, the method comprising the steps of:
(a) parenterally injecting a subject with a targeting composition comprised of a biotin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially accrete at said targeted lesion;
(b) then, parenterally injecting a clearing composition comprised of avidin, and allowing said clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at said targeted lesion;
(c) then, parenterally injecting a detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent, and allowing the conjugate to accrete at said targeted lesion; and
(d) then, parenterally injecting a detection or therapeutic composition comprised of a conjugate of biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing said detection or therapeutic composition to accrete at said targeted lesion.
17. The method of claim 14 for detecting or treating targeted lesions in a patient, the method comprising the steps of: (a) parenterally injecting a subject with a targeting composition comprised of a biotin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially accrete at said targeted lesion;
(b) then, parenterally injecting a clearing composition comprised of avidin, and allowing said clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at said targeted lesion;
(c) then, parenterally injecting a detection or therapeutic composition comprised of a conjugate of biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing the composition to accrete at said targeted lesion; and
(d) then, parenterally injecting another detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent, and allowing the conjugate to accrete at said targeted lesion.
18. The method of claim 14 for detecting or treating targeted lesions in a patient, the method comprising the steps of:
(a) parenterally injecting a subject with a targeting composition comprised of a biotin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially accrete at said targeted lesion; (b) then, parenterally injecting a clearing composition comprised of avidin, and allowing said clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at said targeted lesion; (c) then, parenterally injecting a detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent, and allowing the conjugate to accrete at said targeted lesion; and
(d) then, parenterally injecting a detecting or therapeutic composition comprised of a conjugate of avidin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing said detecting or therapeutic composition to accrete at said targeted lesion.
19. The method of claim 14 for detecting or treating targetd lesions in a patient, the method comprising the steps of:
(a) parenterally injecting a subject with a targeting composition comprised of a biotin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially accrete at said targeted lesion; (b) then, parenterally injecting a clearing composition comprised of avidin, and allowing said clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at said targeted lesion; and
(c) then, parenterally injecting a detection or therapeutic composition comprised of a conjugate of biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing the composition to accrete at said targeted lesion.
20. The method of claim 14 for detecting or treating targeted lesions in a patient, the method comprising the steps of:
(a) parenterally injecting a subject with a targeting composition comprised of a biotin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially accrete at said targeted lesion;
(b) then, parenterally injecting a clearing composition comprised of avidin, and allowing said clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at said targeted lesion; (c) then, parenterally injecting a detection or therapeutic composition comprised of a conjugate of avidin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing said detection or therapeutic composition to accrete at said targeted lesion; and (d) then, parenterally injecting another detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent, and allowing the conjugate to accrete at said targeted lesion.
21. The method of claim 14 for detecting or treating lesions in a patient, the method comprising the steps of:
(a) parenterally injecting a subject with a targeting composition comprised of an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially accrete at said targeted lesion;
(b) then, parenterally injecting a detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent, and allowing the conjugate to accrete at said targeted lesion; and
(c) then, parenterally injecting a detection or therapeutic composition comprised of a conjugate of avidin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing the composition to accrete at said targeted lesion.
22. The method of claim 14 for detecting or treating lesions in a patient, the method comprising the steps of:
(a) parenterally injecting a subject with a targeting composition comprised of an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially accrete at said targeted lesion;
(b) then parenterally injecting a clearing composition comprised of biotin, and allowing said clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at said targeted lesion;
(c) then, parenterally injecting a detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent, and allowing the conjugate to accrete at said targeted lesion; and (d) then, parenterally injecting a detection or therapeutic composition comprised of a conjugate of avidin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing said detection or therapeutic composition to accrete at said targeted lesion.
23. The method of claim 14 for detecting or treating targted lesions in a patient, the method comprising the steps of:
(a) parenterally injecting a subject with a targeting composition comprised of an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially --.ccrete at said targeted lesion;
(b) then, parenterally injecting a clearing composition comprised of biotin, and allowing said clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at said targeted lesion; (c) then, parenterally injecting a detection or therapeutic composition comprised of a conjugate of avidin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing said detection or therapeutic composition to accrete at the targeted lesion; and (d) then, parenterally injecting another detection or therapeutic composition comprised of biotin conjugated to a detection or therapeutic agent, and allowing the conjugate to accrete at said targeted lesion.
24. The method of claim 14 for detecting or treating targeted lesions in a patient, the method comprising the steps of:
(a) parenterally injecting a subject with a targeting composition comprised of an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially accrete at said targeted lesion;
(b) then parenterally injecting a clearing composition comprised of biotin, and allowing said clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at said targeted lesion;
(c) then, parenterally injecting a detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent, and allowing the conjugate to accrete at said targeted lesion; and
(d) then, parenterally injecting a detection or therapeutic composition comprised of a conjugate of biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing said detection or therapeutic composition to accrete at said targeted lesion.
25. The method of claim 1 for detecting or treating targeted lesions in a patient, the method comprising the steps of:
(a) parenterally injecting a subject with a targeting composition comprised of an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially accrete at said targeted lesion;
(b) then, parenterally injecting a clearing composition comprised of biotin, and allowing said clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at said targeted lesion; and
(c) then, parenterally injecting a detection or therapeutic composition comprised of a conjugate of avidin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing said detection or therapeutic composition to accrete at said targeted lesion.
26. The method of claim 14 for detecting or treating lesions in a patient, the method comprising the steps of: (a) parenterally injecting a subject with a targeting composition comprised of an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion, and allowing the protein conjugate to preferentially accrete at said targeted lesion;
(b) then, parenterally injecting a clearing composition comprised of biotin, and allowing said clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at said targeted lesion; (c) then, parenterally injecting a detection or therapeutic composition comprised of a conjugate of biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with said targeted lesion and may be the same as the protein of said targeting composition, and allowing said detection or therapeutic composition to accrete at said targeted lesion; and
(d) then, parenterally injecting another detection or therapeutic composition comprised of avidin conjugated to a detection or therapeutic agent, and allowing the conjugate to accrete at said targeted lesion.
27. The use or method of any of claims 1 or 14, wherein the lesion is cancerous, cardiovascular, infectious or inflammatory.
28. The use or method of claim 27, wherein the cardiovascular lesion is a thrombus, embolus, infarct or atherosclerotic plaque.
29. The use or method of claim 27, wherein the cancerous lesion is a carcinoma, melanoma, sarcoma, neuroblastoma, leukemia, lymphoma, glioma or myeloma.
30. The use or method of claim 27, wherein the lesion is infectious or inflammatory.
31. The use or method of any of claims 1 or 14, wherein the protein is a peptide, polypeptide, hormone, lymphokine, growth factor, albumin, cytokine, enzyme, immune modulator, receptor protein, antibody or antibody fragment.
32. This use or method of any of claims 1 or 14, wherein the protein of the targeting composition and the detection or therapeutic composition are the same.
33. The use or method of any of claims 1 or 14, wherein the protein of the targeting composition and the detection or therapeutic composition are different.
34. The use or method of claim 33, wherein the different proteins preferentially bind to differing epitopes or molecules of the same marker substance.
35. The use or method of claim 31, wherein the protein is a monoclonal antibody, or a specific binding fragment thereof.
36. The use or method of claim 35, wherein the fragment is a Fv, single chain antibody. Fab, Fab', F(ab)2 or
F(ab')2.
37. The use or method of claim 36, wherein the fragment is Fab, Fab', F(ab)2 or F(ab')2.
38. The use or method of claim 35, wherein the antibody is multispecific.
39. The use or method of claim 38, wherein the antibody is multispecific to differing epitopes or molecules of a marker substance.
40. The use or method of claim 31, wherein the protein has a specific immunoreactivity to a marker substance of at least 60% and a cross-reactivity to other antigens or non-target substances of less than 35%.
41. The use or method of any of claims 1 or 14, wherein the method is for detection of a lesion.
42. The use or method of claim 41, wherein the method further comprises external imaging or internal detection.
43. The use or method of claim 42, wherein internal detection is during an operative, intravascular or endoscopic procedure.
44. The use or method of claim 41, wherein the detection agent is a radionuclide, mri enhancing agent, photoactivated dye or differentiation agent.
45. The use or method of claim 44, wherein the radionuclide is a gamma-, positron-, x-ray or fluorescence-emitter.
46. The use or method of claim 44, wherein the differentiation agent is a vitamin, cytokine, autocrine, hormone or drug.
47. The use or method of claim 44, wherein the radionuclide has an energy between 10 and 5000 keV.
48. The use or method of claim 47, wherein the radionuclide has an energy between 50 and 500 keV.
49. The use or method of claim 44, wherein the radionuclide used for imaging is Iodine-123, Iodine-131,
Indium-Ill, Gallium-67, Ruthenium-97, Technetium-99m, Cobalt-57, Cobalt-58, Chromium-51, Iron-59, Selenium-75, Thallium-201, or Ytterbium-169.
50. The use or method of claim 43, wherein the radionuclide used is Iodine-125, Iodine-123, Iodine-131,
Indium-Ill, Technetium-99m or Gallium-67.
51. The use or method of claim 44, wherein the mri enhancing agent is a species of Gadolinium, Iron, Manganese, Rhenium, Europium, Lanthanium, Holmium, or Ferbium.
52. The use or method of any of claims l or 14, wherein the method is for treating a lesion.
53. The use or method of claim 52, wherein the therapeutic agent is an isotope, drug, toxin, fluorescent dye activated by nonionizing radiation, hormone, hormone antagonist, receptor antagonist, autocrine or cytokine.
54. The use or method of claim 52, wherein the therapeutic agent is an electron- or neutron-capturing agent.
55. The use or method of claim 53, wherein the isotope is Iodine-125, Iodine-131, Rhenium-186, Rhenium-188, Silver-Ill, Platinum-197, Palladium-109, Copper-67, Phosphorus-32, Phosphorus-33, Yttrium-90, Scandium-47, Samarium-153, Lutetium-177, Rhodium-105, Praseodymium- 142, Praseodymium-143, Terbium-161, Holmium-166, or Gold- 199.
56. The use or method of claim 52, wherein the therapeutic agent is an anti-DNA, anti-RNA, anti-protein or anti-chromatin cytotoxic or antimicrobial agent.
57. The use or method of claim 53, wherein the drug is taxol, mechlorethamine, cyclophosphamide, melphalan, uracil mustard, chlorambucil, thiotepa, busulfan, carmustine, lo ustine, semustine, streptozocin, dacarbazine, ethotrexate, fluorouracil, cytarabine, azaribine, mercaptopurine, thioguanine, vinblastine, vincristine, dacti omycin, daunorubicin, doxorubicin, bleomycin, mithramycin, mitomycin, L-asparaginase, cisplatin, hydroxyurea, procarbazine, mitotane, prednisone, hydroxyprogesterone caproate, medroprogesterone acetate, diethylstilbestrol, ethinyl estradiol, tamoxifen, and testosterone propionate or fluoxymesterone.
58. The use or method of claim 53, wherein the toxin is abrin, alpha toxin, diphtheria toxin, exotoxin, gelonin, pokeweed antiviral protein, ricin, or saporin.
59. The use or method of claim 53, wherein the drug is puromycin, cycloheximide or ribonuclease.
60. A composition for use in a method for reducing immunogenicity of avidin, wherein the composition comprises avidin coupled with a carbohydrate polymer or polyol groups, which makes the parenterally injected composition less immunogenic.
61. The composition of claim 60, wherein the carbohydrate polymer or polyol groups are dextran, polysaccharides, or polyethylene glycol (PEG) .
62. The use or method of any of claims 1 or 14, wherein the immunogenicity of avidin or of the therapeutic agent conjugate is reduced by coupling the avidin or therapeutic moiety of the conjugate with carbohydrate polymer or polyol groups.
63. The use or method of any of claims 1 or 14, wherein the immunogenicity of the targeting composition is reduced by coupling with a carbohydrate polymer or polyol groups.
64. A sterile injectable composition for human use comprising a detection or therapeutic composition comprised of a conjugate of
(i) avidin, protein and a detection or therapeutic agent, or
(ii) biotin, protein and a detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with a targeted lesion.
65. A kit suitable for use in a method of detecting or treating targeted lesions in a human, the kit comprising: (a) a vial containing a sterile injectable preparation of a targeting composition comprised of
(i) a biotin-protein conjugate, or (ii) an avidin-protein conjugate, wherein the protein preferentially binds to a marker substance produced or associated with the targeted lesion;
(b) optionally, a vial containing a sterile injectable preparation of a clearing composition comprised of (i) avidin, when the targeting composition is a biotin-protein conjugate, or (ii) biotin, when the targeting composition is a avidin-protein conjugate;
(c) a vial containing a sterile injectable preparation of a detection or therapeutic composition which when administered to the human is comprised of a conjugate of
(i) avidin, protein and detection or therapeutic agent, or (ii) biotin, protein and detection or therapeutic agent, wherein the protein preferentially binds to a marker substance produced by or associated with the targeted lesion and may be the same as the protein of the targeting composition; and
(d) optionally, a vial containing a sterile injectable preparation containing another detection or therapeutic composition which when administered to the human is comprised of (i) avidin conjugated to a detection or therapeutic agent, or (ii)biotin conjugated to a detection or therapeutic agent.
PCT/US1993/007754 1992-08-21 1993-08-20 Improved detection and therapy of lesions with biotin/avidin conjugates WO1994004702A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP93920155A EP0656115A4 (en) 1992-08-21 1993-08-20 Improved detection and therapy of lesions with biotin/avidin conjugates.
JP6506499A JPH09505799A (en) 1992-08-21 1993-08-20 Improved detection and treatment of lesions with biotin-avidin complex
AU50184/93A AU671489B2 (en) 1992-08-21 1993-08-20 Improved detection and therapy of lesions with biotin/avidin conjugates
CA002142881A CA2142881A1 (en) 1992-08-21 1993-08-20 Detection and therapy of lesions with biotin/avidin conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/933,982 US5525338A (en) 1992-08-21 1992-08-21 Detection and therapy of lesions with biotin/avidin conjugates
US07/933,982 1992-08-21

Publications (2)

Publication Number Publication Date
WO1994004702A2 true WO1994004702A2 (en) 1994-03-03
WO1994004702A3 WO1994004702A3 (en) 1996-10-03

Family

ID=25464749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/007754 WO1994004702A2 (en) 1992-08-21 1993-08-20 Improved detection and therapy of lesions with biotin/avidin conjugates

Country Status (7)

Country Link
US (2) US5525338A (en)
EP (1) EP0656115A4 (en)
JP (1) JPH09505799A (en)
AU (1) AU671489B2 (en)
CA (1) CA2142881A1 (en)
SG (1) SG47060A1 (en)
WO (1) WO1994004702A2 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023759A1 (en) * 1993-04-22 1994-10-27 Immunomedics, Inc. Improved detection and therapy of lesions with biotin/avidin polymer conjugates
EP0743956A1 (en) * 1993-12-07 1996-11-27 NeoRx Pretargeting methods and compounds
EP0743958A1 (en) * 1994-02-07 1996-11-27 Research Development Foundation Non-viral vector
EP0813425A1 (en) * 1993-07-12 1997-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
WO1998034957A1 (en) 1997-02-11 1998-08-13 Immunomedics, Inc. STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
WO1999061072A2 (en) * 1998-05-29 1999-12-02 President And Fellows Of Harvard College Methods of inhibiting clot formation
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
WO2001097855A2 (en) * 2000-06-20 2001-12-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
US6649163B1 (en) 1996-05-06 2003-11-18 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6730300B2 (en) 1996-03-20 2004-05-04 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
WO2004094613A2 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
EP1649853A2 (en) * 1993-07-29 2006-04-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Microtubule stabilizing agents for treating atherosclerosis or restenosis
US7045605B2 (en) 2001-06-01 2006-05-16 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7112412B1 (en) 1996-05-06 2006-09-26 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer
US7192586B2 (en) 2001-09-20 2007-03-20 Cornell Research Foundation, Inc. Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
WO2008122551A2 (en) 2007-04-04 2008-10-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-epcam antibody and uses thereof
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
EP2057999A2 (en) 1995-12-22 2009-05-13 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
US7771953B2 (en) 2003-01-10 2010-08-10 Millenium Pharmaceuticals, Inc. Methods of diagnosing and treating cancer
US20150283261A1 (en) * 2011-04-04 2015-10-08 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
US10925852B2 (en) 2015-06-30 2021-02-23 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5911969A (en) 1992-06-09 1999-06-15 Neorx Corporation Pretargeting protocols for enhanced localization of active agents to target sites
US5846741A (en) * 1992-08-21 1998-12-08 Immunomedics, Inc. Boron neutron capture therapy using pre-targeting methods
CA2154667A1 (en) * 1993-02-02 1994-08-18 Linda M. Gustavson Directed biodistribution of small molecules
CA2163107C (en) * 1993-05-17 2001-04-17 David Milton Goldenberg Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
TW319763B (en) * 1995-02-01 1997-11-11 Epix Medical Inc
EP0837696B1 (en) * 1995-06-07 2010-02-24 Immunomedics, Inc. Improved delivery of diagnostic and therapeutic agents to a target site
US6106828A (en) * 1996-02-15 2000-08-22 Novo Nordisk A/S Conjugation of polypeptides
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
CA2253904A1 (en) * 1996-05-03 1997-11-13 Immunomedics, Inc. Targeted combination immunotherapy of cancer
JP3794517B2 (en) * 1997-05-08 2006-07-05 日本メジフィジックス株式会社 Tumor diagnostic agent
AU760048B2 (en) * 1998-05-06 2003-05-08 Genentech Inc. Protein purification by ion exchange chromatography
ES2264271T3 (en) * 1998-11-06 2006-12-16 Mitsubishi Kagaku Iatron, Inc. NEW COMPLEXES CONTAINING RETICULATED AVIDINE, PREPARATION PROCEDURE AND ANALYTICAL PROCEDURE FOR THE USE OF THEM.
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
WO2001005433A2 (en) 1999-07-14 2001-01-25 Board Of Regents, The University Of Texas System Delivery and retention of activity agents to lymph nodes
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7897140B2 (en) * 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US7166719B2 (en) 2002-06-27 2007-01-23 Health Research, Inc. Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
WO2001090198A1 (en) * 2000-05-24 2001-11-29 Ludwig Institute For Cancer Research Multicomponent conjugates which bind to target molecules and stimulate cell lysis
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
AU2003249742A1 (en) * 2002-07-02 2004-01-23 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US7534431B2 (en) 2003-01-31 2009-05-19 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
JP3931818B2 (en) * 2003-02-13 2007-06-20 株式会社デンソー Air conditioner for vehicles
NZ564694A (en) * 2003-04-22 2009-11-27 Sod Conseils Rech Applic Peptide vectors
US6936288B2 (en) * 2003-06-10 2005-08-30 Klearsen Corporation Method and composition for the treatment of shingles and related afflictions
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
CA2533878A1 (en) * 2003-07-29 2005-09-22 Immunomedics, Inc. Fluorinated carbohydrate conjugates
WO2005014618A2 (en) * 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US7625549B2 (en) * 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
EP3332808B1 (en) 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
EP2674440B1 (en) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
CA2663121C (en) 2006-09-08 2016-01-19 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
ES2399147T3 (en) 2006-09-08 2013-03-26 Rhode Island Hospital Treatment, prevention and reversal of an alcoholic liver disease
JP2010539245A (en) * 2007-09-14 2010-12-16 日東電工株式会社 Drug carrier
EP2840090B1 (en) 2007-10-30 2018-02-21 Genentech, Inc. Antibody purification by cation exchange chromatography
EP3939617A1 (en) 2009-02-13 2022-01-19 Immunomedics, Inc. Conjugates with an intracellularly-cleavable linkage
WO2010096486A1 (en) * 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
IN2012DN03354A (en) 2009-12-02 2015-10-23 Immunomedics Inc
EP2523680A4 (en) * 2010-01-11 2013-06-19 Ct Molecular Med & Immunology Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
CN107115526A (en) 2011-05-02 2017-09-01 免疫医疗公司 The ultrafiltration concentration of the antibody for the allograft selection applied for small size
US9572787B2 (en) 2011-05-19 2017-02-21 Rhode Island Hospital Inhibition of renal fibrosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
JP2015521602A (en) 2012-06-14 2015-07-30 アンブルックス, インコーポレイテッドAmbrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
CA2884313C (en) 2012-12-13 2023-01-03 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9561291B2 (en) * 2013-03-15 2017-02-07 Imre Kovesdi Methods of targeting T-cells to tumors
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3088898B1 (en) 2013-12-27 2024-02-07 National University Corporation Tokyo Medical and Dental University Method for diagnosis of alzheimer's disease and frontotemporal lobar degeneration, diagnostic agent, therapeutic agent, and screening method for said agents
MX2016010683A (en) 2014-02-21 2017-05-11 Ibc Pharmaceuticals Inc Disease therapy by inducing immune response to trop-2 expressing cells.
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CN106795509A (en) * 2014-03-06 2017-05-31 加利福尼亚大学董事会 Composition and method for measuring cell mechanical stress
CA2953567C (en) 2014-06-24 2023-09-05 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN106999517A (en) 2014-10-07 2017-08-01 免疫医疗公司 The new adjuvant purposes of antibody drug conjugate
CN107428837A (en) 2015-04-22 2017-12-01 免疫医疗公司 Circulate separation, detection, diagnosis and/or the identification of the positive cancer cells of TROP 2
PL3313443T3 (en) 2015-06-25 2023-11-06 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US20170224837A1 (en) 2016-02-10 2017-08-10 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
EP3448260A4 (en) 2016-04-27 2019-10-09 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2019195466A1 (en) * 2018-04-03 2019-10-10 The Trustees Of Columbia University In The City Of New York Compositions for radiotherapy and uses therof
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0251494A2 (en) * 1986-06-23 1988-01-07 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic or radiodiagnostic compound

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283342A (en) * 1992-06-09 1994-02-01 Neorx Corporation Biotinylated small molecules
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4977288A (en) * 1988-01-29 1990-12-11 President And Fellows Of Harvard College M-aminophenyltrialkylstannane
DE3825615A1 (en) * 1988-07-28 1990-02-01 Behringwerke Ag ANTIGENT CONSTRUCTS OF "MAJOR HISTOCOMPATIBILITY COMPLEX" CLASS I ANTIGENS WITH SPECIFIC CARRIER MOLECULES, THEIR PRODUCTION AND USE
JPH04503109A (en) * 1989-01-30 1992-06-04 エピトープ，インコーポレイティド Avidin-biotin assisted immunoassay
DK176290D0 (en) * 1990-07-24 1990-07-24 Novo Nordisk As THERAPEUTIC AND DIAGNOSTIC PREPARATION
IT1245748B (en) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog PREPARATION INCLUDING BIOTINYLATE MONOCLONAL ANTIBODIES, AVIDIN AND BIOTIN, FOR DIAGNOSIS OF CANCER DISEASES AND ITS USE
US6287792B1 (en) * 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
CA2057792C (en) * 1991-12-17 2004-04-20 Kalyan R. Anumula Process for immobilization onto the surfaces of elisa plates of a compound carrier complex and for immunization
US5608060A (en) * 1992-06-09 1997-03-04 Neorx Corporation Biotinidase-resistant biotin-DOTA conjugates
US5482698A (en) * 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0251494A2 (en) * 1986-06-23 1988-01-07 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic or radiodiagnostic compound

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIOTECHNIQUES, Volume 3, No. 6, issued 1985, D.A. FUCCILLO, "Application of the Avidin-Biotin Technique in Microbiology", pages 494-501. *
BYULL. EKSP. BIOL. MED., Volume 109, No. 6, issued 1990, V.V. SINITSYN et al., "Use of Avidin for Enhanced Blood Clearance of Biotinylated Immunoglobulins", pages 567-9. *
CANCER RES., Volume 51, issued 01 November 1991, G. PAGANELLI et al., "Three-Step Monoclonal Antibody Tumor Targeting in Carcinoembryonic Antigen-Positive Patients", pages 5960-5966. *
J. NUCL. MED., Volume 28, issued 1987, D.J. HNATOWICH et al., "Investigations of Avidin and Biotin for Imaging Applications", pages 1294-1302. *
J. NUCL. MED., Volume 31, No. 5, issued May 1990, G. PAGANELLI et al., "Tumor Targeting in Patients with Ovarian Cancer Using Biotinylated Monoclonal Antibodies and Radioactive Streptavidin", Abstract No. 117, page 735. *
J. NUCL. MED., Volume 31, Number 11, issued November 1990, P. KALOFONOS et al., "Imaging of Tumor in Patients with Indium-111-Labeled Biotin and Streptavidin-Conjugated Antibodies: Preliminary Communication", pages 1791-1796. *
See also references of EP0656115A1 *

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416738B1 (en) 1973-12-07 2002-07-09 Neorx Corporation Pretargeting methods and compounds
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US6075010A (en) * 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
WO1994023759A1 (en) * 1993-04-22 1994-10-27 Immunomedics, Inc. Improved detection and therapy of lesions with biotin/avidin polymer conjugates
AU674580B2 (en) * 1993-04-22 1997-01-02 Immunomedics Inc. Improved detection and therapy of lesions with biotin/avidin polymer conjugates
EP0695194A4 (en) * 1993-04-22 1999-03-31 Immunomedics Inc Improved detection and therapy of lesions with biotin/avidin polymer conjugates
EP0695194A1 (en) * 1993-04-22 1996-02-07 Immunomedics, Inc. Improved detection and therapy of lesions with biotin/avidin polymer conjugates
EP0813425A1 (en) * 1993-07-12 1997-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
EP0813425A4 (en) * 1993-07-12 1998-09-09 Neorx Corp Metal radionuclide labeled proteins for diagnosis and therapy
EP1649853A3 (en) * 1993-07-29 2006-11-22 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Microtubule stabilizing agents for treating atherosclerosis or restenosis
EP1649853A2 (en) * 1993-07-29 2006-04-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Microtubule stabilizing agents for treating atherosclerosis or restenosis
EP0743956A4 (en) * 1993-12-07 1999-03-24 Neorx Corp Pretargeting methods and compounds
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
EP0743956A1 (en) * 1993-12-07 1996-11-27 NeoRx Pretargeting methods and compounds
EP0743958A4 (en) * 1994-02-07 1999-07-28 Res Dev Foundation Non-viral vector
EP0743958A1 (en) * 1994-02-07 1996-11-27 Research Development Foundation Non-viral vector
US6132718A (en) * 1994-07-06 2000-10-17 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
EP2057999A2 (en) 1995-12-22 2009-05-13 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
US7348419B2 (en) 1996-03-20 2008-03-25 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications
US6730300B2 (en) 1996-03-20 2004-05-04 Immunomedics, Inc. Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
US6649163B1 (en) 1996-05-06 2003-11-18 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6770450B1 (en) 1996-05-06 2004-08-03 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US7666425B1 (en) 1996-05-06 2010-02-23 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer
US7163680B2 (en) 1996-05-06 2007-01-16 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US7112412B1 (en) 1996-05-06 2006-09-26 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer
WO1998034957A1 (en) 1997-02-11 1998-08-13 Immunomedics, Inc. STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE
WO1999061072A2 (en) * 1998-05-29 1999-12-02 President And Fellows Of Harvard College Methods of inhibiting clot formation
US6534035B1 (en) 1998-05-29 2003-03-18 President And Fellows Of Harvard College Methods of inhibiting clot formation
WO1999061072A3 (en) * 1998-05-29 2000-04-13 Harvard College Methods of inhibiting clot formation
WO2001097855A3 (en) * 2000-06-20 2003-07-31 Immunomedics Inc Targeted combination immunotherapy of cancer and infectious diseases
WO2001097855A2 (en) * 2000-06-20 2001-12-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US7045605B2 (en) 2001-06-01 2006-05-16 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7192586B2 (en) 2001-09-20 2007-03-20 Cornell Research Foundation, Inc. Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
US7771953B2 (en) 2003-01-10 2010-08-10 Millenium Pharmaceuticals, Inc. Methods of diagnosing and treating cancer
WO2004094613A2 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
WO2008122551A2 (en) 2007-04-04 2008-10-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-epcam antibody and uses thereof
US8318911B2 (en) 2007-04-04 2012-11-27 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-EpCAM antibody and uses thereof
US20150283261A1 (en) * 2011-04-04 2015-10-08 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
US9623117B2 (en) * 2011-04-04 2017-04-18 Wisconsin Alumni Research Foundation Method for selective targeting and entry of bacterial toxins to cells
US10925852B2 (en) 2015-06-30 2021-02-23 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof

Also Published As

Publication number Publication date
CA2142881A1 (en) 1994-03-03
EP0656115A4 (en) 1998-09-09
US5698405A (en) 1997-12-16
EP0656115A1 (en) 1995-06-07
SG47060A1 (en) 1998-03-20
AU5018493A (en) 1994-03-15
WO1994004702A3 (en) 1996-10-03
US5525338A (en) 1996-06-11
AU671489B2 (en) 1996-08-29
JPH09505799A (en) 1997-06-10

Similar Documents

Publication Publication Date Title
US5525338A (en) Detection and therapy of lesions with biotin/avidin conjugates
US5482698A (en) Detection and therapy of lesions with biotin/avidin polymer conjugates
US5736119A (en) Detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US5776095A (en) Method and kit for imaging and treating organs and tissues
US5851527A (en) Method for antibody targeting of therapeutic agents
EP0505357B1 (en) Method for antibody targeting of diagnostic or therapeutic agents
JPH08508488A (en) Complex of protein and bifunctional ligand
IE893950A1 (en) Method for antibody targeting of diagnostic or therapeutic¹agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2142881

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993920155

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993920155

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWW Wipo information: withdrawn in national office

Ref document number: 1993920155

Country of ref document: EP